Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance by McCubrey, James A et al.
Oncotarget 2012; 3: 1068-11111068www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, October, Vol.3, No 10
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade 
Inhibitors: How Mutations Can Result in Therapy Resistance and 
How to Overcome Resistance
James A. McCubrey1, Linda S. Steelman1, William H. Chappell1, Stephen L. 
Abrams1, Richard A. Franklin1, Giuseppe Montalto2, Melchiorre Cervello3, Massimo 
Libra4, Saverio Candido4, Grazia Malaponte4, Maria C. Mazzarino4, Paolo Fagone4, 
Ferdinando Nicoletti4, Jörg Bäsecke5, Sanja Mijatovic6, Danijela Maksimovic-
Ivanic6, Michele Milella7, Agostino Tafuri8, Francesca Chiarini9, Camilla Evangelisti9, 
Lucio Cocco10, Alberto M. Martelli9,10
1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA
2 Department of Internal Medicine and Specialties, University of Palermo, Palermo, Italy
3 Consiglio Nazionale delle Ricerche, Istituto di Biomedicina e Immunologia Molecolare “Alberto Monroy”, Palermo, Italy
4 Department of Bio-Medical Sciences, University of Catania, Catania, Italy
5 Department of Medicine, University of Göttingen, Göttingen, Germany
6 Department of Immunology, Instititue for Biological Research “Sinisa Stankovic”, University of Belgrade, Belgrade, Serbia
7 Regina Elena National Cancer Institute, Rome, Italy
8 Sapienza, University of Rome, Department of Cellular Biotechnology and Hematology, Rome, Italy
9 Institute of Molecular Genetics, National Research Council-Rizzoli Orthopedic Institute, Bologna, Italy.
10 Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
Correspondence to: James A. McCubrey, email: mccubreyj@ecu.edu
Keywords: Targeted Therapy, Therapy Resistance, Cancer Stem Cells, Raf, Akt, PI3K, mTOR
Received:  September 12, 2012, Accepted: October 18, 2012, Published: October 20, 2012
Copyright: © McCubrey et al.  This is an open-access article distributed under the terms of the Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
AbstrAct:
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often 
activated by genetic alterations in upstream signaling molecules such as 
receptor tyrosine kinases (RTK). Targeting these pathways is often complex 
and can result in pathway activation depending on the presence of upstream 
mutations (e.g., Raf inhibitors induce Raf activation in cells with wild type 
(WT) RAF in the presence of mutant, activated RAS) and rapamycin can induce 
Akt activation. Targeting with inhibitors directed at two constituents of the 
same pathway or two different signaling pathways may be a more effective 
approach. This review will first evaluate potential uses of Raf, MEK, PI3K, 
Akt and mTOR inhibitors that have been investigated in pre-clinical and 
clinical investigations and then discuss how cancers can become insensitive 
to various inhibitors and potential strategies to overcome this resistance. 
IntroductIon
Predicting sensitivity to small Molecule 
Inhibitors.
Recent studies have examined extensive panels 
of cell lines for mutations of genes implicated in cancer 
as well as for their sensitivity to various inhibitors and 
chemotherapeutic drugs commonly used to treat cancers 
[1,2]. The cell lines were examined by expression 
profiling, chromosome copy number, deep sequencing, 
biostatistical and systems analyses. Both studies indicated 
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that sensitivity to inhibitors was often associated with 
genetic mutations at key elements in the Ras/Raf/
MEK/ERK, PI3K/PTEN/Akt/mTOR and some other 
pathways. One study has generated a “Cancer Cell 
Line Encyclopedia” which will be useful for predictive 
modeling of inhibitor sensitivity [1]. Sensitivity to MEK 
and Raf inhibitors was often investigated in these studies. 
Sensitivity to the B-Raf inhibitor PLX4720 was shown to 
be highly associated with particular mutations at BRAF 
(V600E). Sensitivity to MEK inhibitors was shown to be 
associated with BRAF, NRAS as well as PTEN, PTPN5, 
SPRY2, DUSP4, DUSP6 mutations and to a lesser extent 
mutations at KRAS. Sensitivity to MEK inhibitors in 
NRAS mutant lines was associated with aryl hydrocarbon 
receptor (AHR) expression [2].
overview of Pathway Inhibitors
Effective inhibitors specific for many of the key 
components of the Ras/Raf/MEK/ERK and Ras/PI3K/
PTEN/mTOR pathways have been developed [3-11]. 
In many cases, these inhibitors have been examined in 
clinical trials. Furthermore, inhibitors that target the 
mutant protein more than the wild type (WT) protein 
of various genes (e.g., BRAF and PIK3CA) either have 
been or are being characterized. Thus specific inhibitors 
have been made and some are currently used in the 
clinic. Targeting some components of these pathways has 
proven clinically effective. In some of the diseases, there 
are a very large number of patients with few effective 
treatments [(e.g., Sorafenib and hepatocellular carcinoma 
(HCC)] [11-13]. 
raf/MEK Inhibitors
 Raf inhibitors have been developed and some 
are being used for therapy while others are being 
evaluated in clinical trials. Raf inhibitors have in general 
exhibited greater response rates in clinical trails than 
MEK inhibitors which may be related to the broader 
therapeutic index of Raf inhibitors that suppress ERK 
activity in a mutant-allele specific fashion as opposed to 
MEK inhibitors which suppress MEK activity in tumor 
and normal cells [14]. Some inhibitors (i.e, Sorafenib, 
Bayer) were initially thought to specifically inhibit Raf 
but have been subsequently shown to have multiple 
targets (e.g., VEGF-R, Flt-3, c-Kit, PDGF-R) [15-17]. 
However, that does not preclude their usefulness in 
cancer therapy. Sorafenib is approved for the treatment 
of certain cancers (e.g., renal cell carcinoma (RCC) and 
patients with unresectable HCC). Sorafenib was evaluated 
in the Sorafenib Hepatocellular carcinoma Assessment 
Randomized Protocol (SHARP) trial, which demonstrated 
that the drug was effective in prolonging median survival 
and time-to-progression in patients with advanced HCC 
[11,12]. Sorafenib is generally well tolerated in HCC 
patients with a manageable adverse events profile [11,12]. 
The effects of sorafenib in combination with other drugs 
have been evaluated in HCC [16].
While sorafenib is not considered effective for 
the treatment of most melanomas with BRAF V600E 
mutations, it may be effective in the treatment of a minority 
of melanomas with G469E and D594G mutations which 
express constitutive ERK1/2 but low levels of MEK. 
These melanomas are sensitive to sorafenib, potentially 
because they signal through Raf-1 [18]. MEK inhibitors 
have also been examined for treating HCC in mouse 
models [13] but they do not appear to be as effective 
as Sorafenib, most likely due to the broad specificity of 
Sorafenib, which inhibits other targets besides Raf. An 
overview of where these inhibitors function is presented 
in Figure 1.
PLX-4032 (a.k.a., Zelborab, vemurafenib, 
Plexxikon/Roche) is a B-Raf inhibitor that has and is being 
evaluated in many clinical trials [19-22]. Vemurafenib has 
been approved by the US Food and Drug Administration 
(FDA) for the treatment of patients with unresectable 
or metastatic melanoma carrying the BRAF (V600E) 
mutation. For vemurafenib to be clinically effective, it 
needs to suppress downstream ERK activation essentially 
completely [22]. Vemurafenib is in phase II clinical trials 
(NCT0128653) for patients with metastatic or unresectable 
papillary thyroid cancer (PTC) which have the BRAF 
V600E mutation and are also resistant to radioactive 
iodine therapy. NCT01524978 is a phase I clinical trial 
to evaluate the effects of Vemurafenib on patients with 
multiple myeloma and other cancers containing the BRAF 
V600E mutation. 
PLX-4720 (Plexxikon/Roche) (R7204) is a mutant 
B-Raf specific inhibitor that was used for preclinical 
studies [23]. Our accompanying manuscript published in 
Oncotarget discusses the mutations of various components 
of these pathways as well as their biochemical functions 
[24]. PLX-4720 was designed using a unique screening 
platform developed by Plexxikon that involved the use of 
structural and medicinal chemistry techniques [25]. This 
more selective screening approach has resulted in a series 
of B-Raf inhibitors based on the structural implications 
of BRAF mutation and which discriminate between the 
mutant and WT protein. PLX-4720 is orally available and 
is highly selective for the mutant B-Raf protein. PLX-4720 
is effective against melanomas, as well as colorectal cancer 
(CRC) and other cancers, with the BRAF V600E mutation. 
BRAF V600E has been associated with more aggressive 
tumors and lower rates of patient survival [25].  The IC50 
value for PLX-4720 is approximately 3-fold lower in in 
vitro kinase assays with mutant versus WT B-Raf proteins 
and demonstrates an approximately 60-fold lower IC50 
value in vivo when cell lines with mutant and WT BRAF 
genes are compared [25]. The IC50 value for PLX-4720 
was compared with sorafenib in a panel of melanomas, 
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Figure 1: overview of the ras/raf/MEK/ErK cascade and small Molecule Inhibitors used for targeting this Pathway. 
Activation of this pathway can occur by mutations in upstream growth factor receptors (GFR) or by stimulation by the appropriate growth 
factors (GF). In addition, mutations can occur in intrinsic members of the pathway (RAS RAF, MEK1 or the tumor suppressor Neurofibromin 
(NF1). GFR and GR are indicated in blue. Kinases are indicated in green ovals.  Coupling molecules are indicated by orange ovals. The Ras 
molecule is indicated by a purple oval. Transcription factors are indicated by yellow diamonds. Sites where NF1, protein phosphatase 2A 
(PP2A) Raf kinase inhibitory protein (RKIP), kinase suppressor of Ras (KSR) interact with this pathway are on the right hand side of the 
Ras/Raf/MEK/ERK pathway. NF1, PP2A and RKIP are depicted in black rectangles as they normally serve to dampen the activity of this 
pathway. Molecules such as Mcl-1 which are anti-apoptotic and phosphorylated by ERK and Akt are indicated by blue ovals, other anti-
apoptotic molecule are also indicated by blue ovals. Pro-apoptotic molecules are indicated by black ovals.  Red arrows indicate activating 
events in pathways. Sites where various small molecule inhibitors function are in black octagons on the left hand side of the pathway. 
Representative inhibitors are listed in yellow boxes next to the octagons. Red arrows indicate activating events in pathways. Black arrows 
indicating inactivating events in pathway. Activating phosphorylation events are depicted in red circles with Ps with a black outlined circle. 
Inactivating phosphorylation events are depicted in black circles with Ps with a red outlined circle.
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CRC and non small cell lung cancer (NSCLC). The BRAF 
gene status was known in all of these cell lines. The IC50 
value for PXL-4720 was approximately 100-fold lower 
(range: 17.5 to 280 nM) than sorafenib in melanomas and 
colon carcinomas that had the BRAF V600E mutation; 
however, the IC50 value for PLX-4720 was approximately 
the same as sorafenib in colon carcinomas and NSCLC 
without BRAF mutations, but with RAS mutations. PLX-
4720 arrests mutant but not WT BRAF melanoma cells at 
the G0/G1 cell-cycle stage and initiates apoptosis in these 
cells.
Studies examining the effects of sorafenib on 
sorafenib-resistant cell lines transfected with BRAF genes 
containing gatekeeper mutations indicated that the mutant 
B-Raf signaling was resistant to sorafenib, but sorafenib 
still inhibited tumor growth driven by the mutant B-Raf 
protein. In essence sorafenib was inhibiting Raf-1 activity 
which was induced by the mutant B-Raf protein. In 
contrast, PLX-4720 inhibited tumor growth by targeting 
oncogenic B-Raf. These studies indicated that sorafenib 
suppressed tumor growth independently of B-Raf while 
PLX-4720 directly inhibited the oncogenic effects of 
B-Raf [26]. 
GSK2118436 (a.k.a. dabrafenib) is an ATP-
competitive inhibitor of mutant B-Raf, WT B-Raf and 
WT Raf-1 developed by GlaxoSmithKlein (GSK) in 
clinic trial (NCT00880321), which examined patients with 
melanoma, brain metastases, in other solid tumours it was 
determined to be safe and elicited responses. It was an 
active inhibitor of BRAF V600E in this trial [27].
CCT239065 is a mutant B-Raf inhibitor developed 
at the Institute of Cancer Research in London, UK [28]. 
It inhibits BRAF mutant allele (V600E) signaling and 
proliferation more than WT BRAF-mediated signaling. 
Its effects are more selective for cells containing mutant 
BRAF than WT BRAF. CCT239065 is well tolerated in 
mice and had good oral bioavailability. It suppressed 
tumors containing BRAF mutant genes but not WT BRAF 
tumors in mice tumor xenograft studies [28]. 
GDC-0879 is a BRAF mutant allele selective 
inhibitor developed by Genentech which has been 
evaluated in pre-clinical studies [29].  The efficacy GDC-
0879 is related to the BRAF V600E mutational status in 
the cancer cells and inhibition of downstream MEK and 
ERK activity. 
PLX5568 is a selective Raf kinase inhibitor 
developed by Plexicon. It is being examined for the 
treatment of polycystic kidney disease (PKD). In the 
kidney, Raf-1 is localized to the tubular cells where it 
is linked to many physiologically important functions. 
PLX5568 suppressed cyst enlargement in a rat model of 
PKD but did not improve kidney function as fibrosis was 
not suppressed [30]. 
Raf-265 is an ATP-competitive pan-Raf inhibitor 
developed by Novartis. Treatment of bronchus carcinoid 
NCI-H727 and insulinoma cells (CM insulinoma cell 
line) with Raf-265 enhanced sensitivity to TRAIL-
induced apoptosis. These cells are normally resistant to 
PI3K/mTOR inhibitors when combined with TRAIL. 
Raf-265 was shown to decrease Bcl-2 levels which 
correlated with their sensitivity to TRAIL-mediated 
apoptosis. This approach may be effective in the therapy 
of neuroendocrine tumors [31]. Raf-265 is being evaluated 
in a clinical trial (NCT00304525) for treatment of patients 
with locally advanced or metastatic melanoma.
Regorafenib (BAY 73-4506) is an oral multikinase 
inhibitor of angiogenic, stromal and oncogenic RTKs 
developed by Bayer. Regorafenib inhibits RTKs such as 
VEGF-R2, VEGF-R1/3, PDGF-Rβ, fibroblast growth 
factor receptor-1 as well as mutant Kit, RET and B-Raf. 
The effects of regorafenib on tumor growth have been 
evaluated in human xenograft models in mice, and tumor 
shrinkages were observed in breast MDA-MB-231 and 
renal 786-O carcinoma models [32].
AZ628 is a selective Raf inhibitor developed by 
Astra Zenica. BRAF-mutant melanoma cells are normally 
very sensitive to AZ628. However, when AZ628 cells 
are grown for prolonged periods of time, they become 
resistant to AZ628 by upregulating the expression of Raf-
1 [33].
XL281 is an orally-active WT and mutant RAF 
kinases selective inhibitor developed by Exelixis and 
Bristol-Myers Squibb. It has been examined in clinical 
trials primarily with patients having BRAF mutations 
(CRC, melanoma, PTC and NSCLC) [34].
results of clinical trials with sorafenib.
Some of first clinical trials with Raf inhibitors 
were with sorafenib (NexavarTM) in metastatic RCC [35]. 
Clinical trials with melanoma were also done around the 
same time period [36]. The clinical trials with melanoma 
patients and sorafenib as a single agent did not yield 
encouraging results.  Due to the broad specificity of 
sorafenib this drug has been evaluated for the therapy of 
diverse cancers, including RCC, melanoma and HCC (due 
to the involvement of the Raf/MEK/ERK cascade, as well 
as altered VEGFR pathway in these cancers) and gastro-
intestinal stromal tumors (GIST) (due to the involvement 
of KIT mutations in this cancer). Sorafenib has been 
approved for the treatment of renal cancer, including 
RCC in 2005 and for HCC in 2007. Although BRAF is not 
mutated in RCC, VEGFR-2 may be aberrantly expressed 
as there is dysregulation of its cognate ligand VEGF which 
can activate VEGFR2 and the Raf/MEK/ERK cascade. 
Sorafenib is active as a single agent in RCC, probably due 
to its ability to suppress the activities of essential growth-
required signaling pathways. 
Phase II and larger phase III clinical trails with 
sorafenib combined with chemotherapy or targeted 
therapy were performed. NCT00461851 was a phase II 
trial with bladder cancer patients. It combined sorafenib 
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with gemcitabine and carboplatin. NCT01371981 was a 
phase II/III with sorafenib and the proteosomal inhibitor 
bortezomib as well as various chemotherapeutic drugs 
including asparaginease, cytarabine, daunorubicin and 
mitoxantrone in patients with acute myeloid leukemia 
(AML) and yielded variable results with low response 
rates [38]. 
Effects of sorafenib on Melanomas.
As the BRAF gene is mutated in approximately 50 to 
70% of melanomas, sorafenib was evaluated for its ability 
to suppress melanoma growth in mouse models [39]. Most 
BRAF mutations occur at V600E. Sorafenib had only 
modest activity as a single agent in advanced melanoma 
Figure 2: sites of Mutations which can result in resistance to raf and MEK Inhibitors. Sites of mutation which result in 
sensitivity to Raf and MEK inhibitors are indicated in red irregular circles. The same color scheme present in Figure 1 for other signaling 
molecules is continuted in this figure. Signaling induced by mutations is indicated by red dashed lines. Secondary mutation/events which 
result in inhibitor resistance are depicted in yellow irregular circle. Signaling induced by mutations is indicated by red dashed lines.
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and it did not appear to be more effective in the treatment 
of melanomas that are either WT or mutant at the BRAF 
gene, hence it may be targeting a kinase other than B-Raf 
in these melanomas (e.g., VEGFR or Raf-1). Alternatively, 
it could be targeting an upstream receptor kinase which 
signals through the Ras/Raf/MEK/ERK cascade. It is 
relevant to examine the effects of combining sorafenib 
with a MEK inhibitor to treat malignant melanoma and 
certain other cancers. Sorafenib may target the VEGFR 
and other membrane receptors expressed on the particular 
cancer cells, whereas the MEK inhibitor would specifically 
suppress the Raf/MEK/ERK cascade which is abnormally 
activated by the BRAF oncogene or other mutant upstream 
signaling molecules. To improve the effectiveness of 
sorafenib in the therapy of melanoma, it is being combined 
with standard chemotherapeutic drugs. 
results of clinical trials with Vemurafenib.
Phase I, II and III clinical trials with vemurafenib 
have been performed. A greater than 90% reduction in 
active ERK was necessary for clinical response [22]. In 
the phase III clinical trial comparing vemurafenib with 
the standard of care chemotherapeutic drug decarbazine, 
the trial was terminated prematurely as it was apparent 
that vemurafenib was more effective than decarbazine 
[40]. Vemurafenib was approved for the treatment of 
unresectable metastatic BRAF mutant melanoma in 
2011. Recently, the results of a phase II clinical trial 
(NCT00949702) indicated that vemurafenib induces 
clinical responses in greater than 50% of previously 
treated mutant BRAF (V600E or V600K) melanoma 
patients the median overall survival was approximately 
16 months [41]. 
results of clinical trials with dabrafenib 
(GsK2118436).
 Dabrafenib has also displayed positive results in 
Phase I/II trials [42,43]. Dabrafenib is in ongoing Phase II 
clinical trials (NCT01153763) as a single agent in patients 
with BRAF mutant melanoma. 
need for Genetic screening before treatment 
with raf Kinase Inhibitors.
It is critical to determine the genetic status at both 
BRAF and RAS before treatment with Raf inhibitors 
[44-46]. Class I B-Raf inhibitors (active conformation 
inhibitors) such as (vemurafenib and dabrafenib) will 
inhibit BRAF mutants, however these ATP-competitive 
B-Raf inhibitors will not inhibit WT B-Raf in the presence 
of activated Ras expression. In fact, these B-Raf inhibitors 
can activate Raf-1 in these cells in the presence of active 
Ras. The Raf inhibitors can induce B-Raf binding to Raf-1. 
Vemurafenib can, to a lesser extent, induce B-Raf binding 
to Raf-1 when the ERK-mediated negative feedback loop 
on B-Raf was inhibited with a MEK inhibitor. These 
binding events were determined to require the presence of 
activated Ras (WT or mutant), which may be necessary for 
the translocation from the cytoplasm to the membrane and 
assembly into the signaling complex. This has therapeutic 
implications, as after treatment of patients with mutant 
RAS with certain B-Raf inhibitors, B-Raf can bind and 
activate Raf-1 and promote the oncogenic pathway. In 
fact, even kinase-dead BRAF mutations, which have been 
observed in human cancer [47], the mutant B-Raf proteins 
can dimerize with Raf-1, when stimulated by the mutant 
Ras protein and activate the Raf/MEK/ERK cascade. For 
Raf-selective inhibitors to be therapeutically useful, prior 
screening of patients for RAS mutations will be necessary, 
as well as perhaps additional screening during treatment. 
Otherwise resistance may develop and lead to further 
stimulation of the Raf/MEK/ERK cascade. 
ATP-competitive Raf inhibitors inhibit ERK 
signaling in cells with mutant BRAF, but enhance 
signaling in cells with WT BRAF. Drug-mediated 
transactivation of Raf dimers was shown to be responsible 
for the activation of the enzyme by inhibitors. The Raf 
inhibitors bind to the ATP-binding site of the Raf dimer. 
The inhibitors can also bind to B-Raf:Raf-1 heterodimers. 
Raf activity is dependent on Ras activity. The Raf inhibitor 
binding to one Raf protomer results in the inhibition of 
that protomer, but activation of the remaining protomer. 
RAS is not normally mutated in cells with BRAF mutants 
and there is minimal Ras activity. Hence in BRAF-
mutant cells, Raf inhibitors will be effective in inhibiting 
downstream MEK:ERK signaling. However in cells with 
active Ras, they will not [44,45]. These basic science 
observations have been essentially confirmed in clinical 
trials [19,20,22]. 
Raf activation occurs after treatment of certain 
cancer patients with Raf inhibitors. This abnormal 
Raf activation can lead to skin diseases such as 
keratoacanthomas (KAs) and cutaneous squamous cell 
carcinomas (cSCCs) in patients with RAS mutations. 
These results indicate that co-targeting with Raf and MEK 
inhibitors may be appropriate in patients who have active 
Raf and B-Raf [48,49].  
resistance to raf Inhibitors.
A problem with treatment of melanoma patients 
with mutant BRAF is the emergence of inhibitor-resistance 
which occurs frequently and relatively rapidly after 
treatment with the Raf inhibitors (2-18 months) [50]. 
This may be due to the persistence of melanoma cancer 
initiating cells (CICs) [51-54]. Some of these CICs may 
have other mutations besides BRAF.
There are many different mechanisms by which 
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Figure 3: overview of the PI3K/Akt/mtor cascade and small Molecule Inhibitors used for targeting this Pathway. 
Activation of this pathway can occur by mutations in upstream growth factor receptors (GFR) or by stimulation by the appropriate GF. In 
addition mutations can occur in intrinsic members of the pathway (RAS PIK3CA, AKT or the tumor suppressors (NF1, PTEN, TSC1, TSC2). 
Sites where NF1, PTEN, TSC1, TSC2 are depicted in black rectangles as they normally serve to dampen the activity of this pathway. An 
activated growth factor receptor is indicated in blue. Ras and Rheb are indicated in dark blue ovals. IRS1, SOS, Shc and Grb2 are indicated 
in orange ovals. Kinases are indicated in green ovals. The p85 regulatory subunit of PI3K is indicated in a red oval. Phosphatases are 
indicated in black octagons. NF1, TSC1 and TSC2 are indicated in black squares. PIP2 and PIP3 are indicated in yellow ovals. mTOR 
interacting proteins which positively regulate mTOR activity are indicated in yellor ovals. mTOR interacting proteins which negatively 
regulate mTOR activity are indicated in black ovals. Transcription factors activated by either ERK or Akt phosphorylation are indicated in 
yellow diamonds. The Foxo transcription factor that is inactivated by Akt phosphorylation is indicated by a black diamond.  β-catenin is 
indicated in an orange rectangle. mRNA initiation factors and proteins associated with the ribosome are indicated in purple ovals. mTORC1 
phosphorylates the unc-51-like kinase 1 (ULK1) which results in the suppression of autophagy. ULK1 is indicated in a black oval. The 
mTORC1 inhibitor prevents phosphorylation of ULK1 and autophagy can occur. Sites where various small molecule inhibitors function 
are in black octagons. Representative inhibitors are listed in boxes in yellow next to the octagons. Red arrows indicate activating events 
in pathways. Black arrows indicating inactivating events in pathway. Activating phosphorylation events are depicted in red circles with Ps 
with a black outlined circle. Inactivating phosphorylation events are depicted in black circles with Ps with a red outlined circle.
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melanoma cells can become resistant to Raf inhibitors 
[55]. Unlike resistance mechanisms observed in some 
other cancers such as imatinib-resistant chronic myeloid 
leukemia (CML) where the resistant cells often have 
mutations in the gatekeeper residues in BCRABL which 
allows the cells to proliferate and activate additional 
signaling pathways in the presence of imatinib, others 
mechanism for Raf inhibitor-resistance are more frequently 
observed in cells containing BRAF mutants. Gatekeeper 
mutations in BRAF can be created experimentally, and 
the cells are resistant to the B-Raf specific inhibitors, but 
these mutations do not appear to occur frequently in B-Raf 
inhibitor-resistant clinical specimens [50,59,60]. 
Poulikakos and colleagues demonstrated a novel 
resistance mechanism which involves a splice variant 
in the mutated BRAF allele that leads to a loss of the 
Ras binding domain in the B-Raf protein that prevents 
dimerization. This mutant form of BRAF V600E elicits 
enhanced dimerization in cells which contain low levels 
of active Ras, in comparison to cells containing the full-
length BRAF V600E mutation. The truncated B-Raf 
V600E kinase can dimerize with Raf-1 and induce 
downstream MEK/ERK in the absence of activating Ras 
mutations and the cells are resistant to the Raf inhibitors 
[61]. This splicing mutation was determined to be present 
in BRAF V600E in six of nineteen vemurafenib-treated 
patient samples which had undergone relapse. 
Many different types of gene deregulation events 
have been observed in B-Raf inhibitor-resistant cells 
[62,63]. Mutations at cyclin-dependent kinase 4 (CDK4) 
and amplification of cyclin-D1 have been documented in 
clinical specimens from B-Raf inhibitor-treated patients 
which underwent remission [64]. A diagram illustrating 
some of the mechanisms by which cells become resistant 
to Raf and MEK inhibitors is presented in Figure 2.
Amplification of the B-Raf gene has been reported 
in some B-Raf inhibitor-resistant cells [65]. The B-Raf 
gene was determined to be amplified in a subset of some 
treatment-naïve cells. The authors of this study determined 
that treatment with B-Raf and MEK inhibitors eliminated 
resistance of the cells. An additional study observed that 
the mutant BRAF V600E gene was amplified in 4 out 
of 20 melanoma patients which were resistant to B-Raf 
inhibitors [66]. This mechanism of B-Raf inhibitor-
resistance is distinct from resistance generated by NRAS 
mutations or overexpression as the cells with amplified 
BRAF V600E were independent of Raf-1 expression while 
N-Ras-mediated inhibitor resistance was dependent on 
Raf-1 expression.
In an attempt to identify genes which could 
potentially confer resistance to B-Raf inhibitors, one 
group expressed a panel of approximately 600 kinase-
related open reading frames in normally B-Raf inhibitor-
sensitive A375 melanoma cells, which contain the BRAF 
V600E mutation [67]. This group identified mitogen-
activated protein kinase kinase kinase 8 (MAP3K8) 
which encodes the serine-threonine protein kinase COT/
Tp12 (cancer Osaka thyroid oncogene/ tumor progression 
locus-2) as a MAPK pathway agonist which drives 
resistance to Raf inhibition in BRAF mutant cell lines. 
COT was demonstrated to induce ERK via MEK but 
independent of Raf [67]. COT expression was observed to 
inversely correlate with BRAF V600E expression which 
may suggest that B-Raf may downregulate COT protein 
levels by destabilizing the protein. When BRAF V600E 
expression decrease due to B-Raf inhibitor treatment, the 
levels of COT are predicted to rise. Combining B-Raf 
and MEK inhibitors would overcome the resistance to 
the B-Raf inhibitors in the cells which overexpressed 
COT. The genomic region surrounding MAP3K8 (COT) 
was amplified in 2 out of 38 BRAF-mutant cell lines. 
These lines had not previously been treated with B-Raf 
inhibitors. The lines with amplified MAP3K8 (COT) were 
demonstrated to be resistant to B-Raf inhibitors. COT 
expression was determined to be increased in expression in 
some relapse patients. COT inhibitors are being developed 
and may be effective in overcoming the resistance present 
in some B-Raf inhibitor-resistant tumors [68]. 
The DNA sequences of 138 cancer genes from tumor 
cells isolated from a patient that initially was sensitive to 
the vemurafenib which became resistant after treatment 
were examined [50]. This study observed that there was a 
mutation in MEK1 (C121S) in the vemurafenib-resistant 
tumor which was not present in the original tumor. The 
MEK1 C121S mutation conferred resistance to both Raf 
and MEK inhibitors. 
In another study with B-Raf inhibitor-resistant 
patient samples, the resistant cells were observed 
to have mutations at NRAS or overexpress PDGFR-
beta [60]. These authors indicated that resistance to 
B-Raf inhibitors was not due to secondary mutations at 
BRAF, but activation of additional signaling pathways 
by PDGFR-beta or by N-Ras activation of the Raf/
MEK/ERK pathway. PDGFR-beta was observed to be 
hyperphosphorylated in the cells from one B-Raf inhibitor-
resistant line, but surprisingly the cells were not sensitive 
to imatinib which can target PDGFR-beta.
Other studies have indicated that switching of 
Raf isoforms may confer resistance to B-Raf inhibitors. 
Switching from B-Raf to either Raf-1 or A-Raf was 
observed after incubation of melanoma cells containing 
the BRAF V600E mutation in the presence of the B-Raf 
inhibitor dabrafenib for prolonged periods of time in 
the recovered inhibitor-resistant cells. In these inhibitor-
resistant cells, they expressed other isoforms of Raf 
(e.g., Raf-1 or A-Raf) (69). In this study some inhibitor-
resistant cells were also observed to overexpress IGF-1R 
which can also induce the expression of the PI3K/PTEN/
Akt/mTOR pathway. Combined treatment with IGF-1R/
PI3K and MEK inhibitors eliminated the resistance of the 
cells. Increased expression of IGF-1R and activation of 
Akt was also demonstrated in one of five paired specimens 
Oncotarget 2012; 3: 1068-11111076www.impactjournals.com/oncotarget
obtained from post-relapse vemurafenib-treated patients as 
compared to the patient samples prior to treatment. 
Suppression of pro-apoptotic Bim expression 
is a mechanism of resistance to B-Raf inhibitors [70]. 
PTEN-mutant cells display decreased levels of Bim. 
Often melanoma cells with BRAF mutations also contain 
PTEN or PIK3CA mutations. Vemurafenib increases Bim 
expression in PTEN WT cells. The involvement of Akt-3 
and FOXO3a was reported in these studies. Combining 
B-Raf and PI3K inhibitors enhanced Bim expression via 
FOXO3a in the PTEN-mutant cells.  
In a study of Raf265-resistant melanomas containing 
the BRAF V600E mutation, it was observed that protein 
kinase D3 (PRKD3) mediated resistance to both Raf 
and MEK inhibitors and siRNA knockdown of PRKD3 
cooperated with Raf265 in suppressing the growth of the 
resistant melanoma cells [71]. CID755673 is a PRKD3 
inhibitor [72]. Potentially CID755673 could be combined 
with B-Raf inhibitors to suppress the growth of certain 
B-Raf inhibitor-resistant melanomas.
Dabrafenib-resistant A375 melanoma cells were 
isolated by culturing the cells in dabrafenib. The resistant 
cells were also resistant to vemurafenib and the MEK 
inhibitor trametinib (GSK112012, an allosteric MEK 
inhibitor), in frame deletions of MEK1 and mutations at 
NRAS mutations were observed in some cells. The in frame 
deletions of MEK occurred at MEK1 K59del, the NRAS 
mutations occurred at NRAS Q61K and A146T in the 
presence and absence of the MEK1 P387S mutation in the 
A375 BRAF V600E line and NRAS Q61K in the YUSIT1 
BRAF V600K line. The combination of dabrafenib 
and trametinib suppressed cell growth in the resistant 
lines. These results are somewhat surprising as some 
of the resistant lines had NRAS mutations. N-Ras could 
potentially activate PI3K/PTEN/Akt/mTOR pathway 
which could promote resistance to these inhibitors. The 
combination of the PI3K inhibitor GSK2126458 and either 
B-Raf or MEK inhibitors enhanced growth suppression 
and decreased ribosomal S6 protein phosphorylation [27]. 
Combination clinical trials are planned based on these 
results.
Two recent studies have indicated that the tumor 
microenviroment may contribute to the resistance to 
B-Raf and other small molecule inhibitors. The tumor 
Figure 4: sites of Mutation which can result in resistance to mtor Inhibitors. Sites of mutation which result in resistance 
to mTOR inhibitors are indicated in yellow irregular circles. The same color scheme present in Figures 1, 2 and 3 is continued in this figure.
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microenviroment can secrete growth factors such 
as hepatocyte growth factor (HGF) which results in 
activation of the HGF receptor MET and subsequent 
downstream Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR 
signaling which results in resistance to the small molecule 
inhibitors [73,74]. 
MEK Inhibitors
Specific inhibitors of MEK have been developed: 
PD98059, PD184352 (a.k.a. CI-1040), PD0325901 (all 
Pfizer), U0126 (DuPont), Selumetinib (a.k.a., ARRY-
142886, AZD6244) (Astra-Zeneca), MEK162/ARRY-
162 (Novartis), GDC-0973 (Genentech), RDEA119/
Refametinib (Ardea Biosciences/Bayer), GSK112012 
(GlaxoSmithKlein), TAK-733 (Takeda San Diego, 
Millennium Pharmaceuticals, Inc), RO4987655 (Roche) 
and AS703026 (EMD Serono)  [3-5,13,75-85]. 
MEK inhibitors differ from most other kinase 
inhibitors as they do not compete with ATP binding 
(non-ATP competitive), which confers a high specificity 
[75]. Most MEK inhibitors are specific and do not inhibit 
many different protein kinases [75-79] although as will 
be discussed below, certain MEK inhibitors are more 
specific than others. The crystal structures of MEK1 and 
MEK2 have been solved as ternary complexes with ATP 
and PD184352, and have revealed that both MEK1 and 
MEK2 have unique inhibitor binding sites located on a 
hydrophobic pocket adjacent to, but not overlapping with, 
the ATP-binding site [75].  Furthermore, effective targeting 
of MEK1/MEK2 is highly specific, as ERK1/ERK2 are 
the only well-described downstream targets. A distinct 
advantage of inhibiting MEK is that it can be targeted 
without knowledge of the precise genetic mutation that 
results in its aberrant activation. This is not true with 
targeting Raf as certain Raf inhibitors will activate Raf and 
also certain B-Raf-specific inhibitors will not be effective 
in the presence of RAS mutations as discussed above. 
An advantage of targeting MEK is that the Ras/
Raf/MEK/ERK pathway is a convergence point where 
a number of upstream signaling pathways can be 
blocked with the inhibition of MEK. For example, MEK 
inhibitors, such as selumetinib (AZD6244), are also being 
investigated for the treatment of pancreatic cancers, 
breast cancers, and other cancers such as hematopoietic 
malignancies, including multiple myeloma [75]. 
ClinicalTrials.gov lists 49 clinical trials for Selumetinib, 
either as a single agent or combined with another inhibitor 
or combinined with chemotherapy or radiotherapy.
Selumetinib inhibits MEK1 in vitro with an IC50 
value of 14.1 ± 0.79 nM [79]; it is specific for MEK1 
as it did not appear to inhibit any of the approximately 
40 other kinases in the panel tested. Selumetinib is not 
competitive with ATP. Molecular modeling studies 
indicate that selumetinib binds to an allosteric binding 
site on MEK1/MEK2. The binding sites on MEK1/MEK2 
are relatively unique to these kinases and may explain 
the high specificity of MEK inhibitors. This binding may 
lock MEK1/2 in an inactivate conformation that enables 
binding of ATP and substrate, but prevents the molecular 
interactions required for catalysis and access to the ERK 
activation loop. In basic research studies, treatment with 
the MEK inhibitor resulted in the detection of activated 
MEK1/2 when the western blot is probed with an antibody 
that recognizes active (phosphorylated) MEK1/2, while 
downstream ERK1/2 did not appear activated with the 
activation specific ERK1/2 antibody [13,79]. Selumetinib 
inhibited downstream ERK1/ERK2 activation in in vitro 
cell line assays with stimulated and unstimulated cells, 
and also inhibited activation in tumor-transplant models. 
Selumetinib did not prevent the activation of the related 
ERK5 that occurs with some older MEK1 inhibitors, 
which are not being pursued in clinical trials. Inhibition 
of ERK1/2 suppresses their ability to phosphorylate and 
modulate the activity of Raf-1, B-Raf and MEK1 but not 
MEK2 as MEK2 lacks the ERK1/ERK2 phosphorylation 
site. In essence, by inhibiting ERK1/2 the negative loop of 
Raf-1 and MEK phosphorylation is suppressed and hence 
there will be an accumulation of activated Raf-1 and MEK 
[13,79]. This biochemical feedback loop may provide a 
rationale for combining Raf and MEK inhibitors in certain 
therapeutic situations.
In colon, melanoma, pancreatic, liver and some 
breast cancers, selumetinib inhibited the growth of tumors 
in tumor xenograft studies performed in mice. The new 
MEK inhibitors are also at least 10 to 100-fold more 
effective than earlier MEK inhibitors and hence can be 
used at lower concentrations [13,79]. Selumetinib also 
inhibits the growth of human leukemia cells, but does not 
affect the growth of normal human cells. Selumetinib also 
suppressed the growth of pancreatic BxPC3 cells, which 
do not have a known mutation in this pathway, suggesting 
that this drug may also be useful for treating cancers 
that lack definable mutations. However, it is likely that 
BxPC3 cells have some type of upstream gene mutation/
amplification or autocrine growth factor loop that results 
in activation of the Raf/MEK/ERK pathway.
Selumetinib induced G1/S cell-cycle arrest in colon 
and melanoma cancer cell lines and activated caspase-3 
and -7 in some cell lines (Malme3M and SKMEL2); 
however, caspase induction was not observed in other 
melanoma (SKMEL28) or colon cancer cell lines (HT29), 
demonstrating that further research needs to be performed 
with this inhibitor to determine if it normally induces 
apoptosis and whether the induction of apoptosis can be 
increased with other inhibitors or chemotherapeutic drugs. 
Selumetinib suppressed the tumor growth of 
pancreatic cells, such as BxPC3, in immunocompromised 
mice more effectively than conventional chemotherapeutic 
drugs, such as gemcitabine, which is commonly used to 
treat pancreatic cancer; however, once treatment with 
selumetinib was discontinued, the tumors reappeared 
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[13,79]. Most likely MEK inhibitors do not induce 
apoptosis, but rather, they inhibit proliferation. That is, 
MEK inhibitors are cytostatic. 
PD-184352 (Pfizer) was the first MEK inhibitor 
to enter clinical trials and it demonstrated inhibition of 
activated ERK and anti-tumor activity in patients [75]; 
however, subsequent multicenter, phase II studies with 
patients with diverse solid tumors did not demonstrate 
encouraging results [75]. This was probably due to low 
oral bioavailability and high metabolism, which led to 
plasma drug levels that were inadequate to suppress tumor 
growth.
The subsequent PD-0325901 MEK inhibitor is 
an orally-active, potent, specific, non-ATP competitive 
inhibitor of MEK. PD-0325901 demonstrated improved 
pharmacological and pharmaceutical properties compared 
with PD-184352, including a greater potency for inhibition 
of MEK, and higher bioavailability and increased 
metabolic stability. PD-0325901 has a Ki value of 1 nM 
against MEK1 and MEK2 in in vitro kinase assays. PD-
0325901 inhibits the growth of cell lines that proliferate 
in response to elevated signaling of the Raf/MEK/ERK 
pathways [75]. Clinical trials with PD-0325901 have 
documented some successes and some adverse side effects 
[75]. MEK inhibitors may be appropriate to treat only 
those cancers that proliferate in response to activation of 
the Raf/MEK/ERK pathway [75]. Furthermore, it may also 
be important to include an additional pathway inhibitor, 
chemotherapeutic drug or radiation treatment to induce 
death of the cancer cell.  There is a phase I clinical trial 
(NCT01347866) examining the effects of combining PD-
0329501 with the PI3K/mTOR inhibitor PF-04691502. 
Initially this phase I trial will examine toxicity in patients 
with advanced cancers. If tolerable toxicity levels are 
observed, then additional studies will be perfomed with 
CRC patients containing mutant KRAS genes who have 
had previous therapy. 
RDEA119/Refametinib is a more recently described 
MEK inhibitor developed by Ardea Biosciences [83-
85]. It is a highly selective MEK inhibitor that displays 
a >100-fold selectivity in kinase inhibition in a panel of 
205 kinases. In contrast, in the same kinase specificity 
analysis, other recently developed MEK inhibitors (e.g., 
PD0325901) also inhibited the Src and RON kinases [83-
85]. 
Trametinib (GSK1120212) is an allosteric MEK 
inhibitor developed by GSK. It has been shown to be 
effective when combined with dabrafenib in certain 
dabrafenib-resistant BRAF V600  melanoma lines that also 
had mutations at NRAS or MEK1 [86]. The combination 
Figure 5: rationale for targeting both the ras/raf/MEK/ErK and ras/PI3K/PtEn/Akt/mtor Pathways for 
suppressing Inhibitor resistant cells. Initial mutations are depicted in red irregular circle. Secondary mutation/events which result 
in inhibitor resistance are depicted in yellow irregular circle. Potential combination inhibitor therapeutic approaches are indicated in black 
octagons. The remaining color scenarios are as presented in Figures 1, 2, 3 and 4. Normal activating signaling is indicated in either solid 
red or solid black lines. Signaling induced by mutations is indicated by red dashed lines.
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of trametinib and the PI3K/mTOR dual inhibitor 
GSK2126458 also enhanced cell growth inhibition in 
these B-Raf inhibitor-resistant BRAF mutant melanoma 
lines.
GDC-0973 (XL518) is a potent and selective MEK 
inhibitor developed by Genentech [78,87]. The effects of 
combining GDC-0973 and the PI3K inhibitor GDC-0941 
on the proliferation of BRAF and KRAS mutant cancer 
cells indicated combination efficacy both in vitro and in 
vivo.
AS703026 (MSC1936369B) is a MEK inhibitor 
developed by EMD Serono. AS703026 suppressed 
cetuximab-resistant CRCs which had KRAS mutations 
both in vitro and in vivo models [88]. AS703026 inhibited 
growth and survival of multiple myeloma (MM) cells 
and cytokine-induced differentiation more potently 
than selumetinib and importantly AS703026 was 
cytotoxic, where as most MEK inhibitors are cytostatic 
[89]. AS703026 sensitized MM cells to a variety of 
conventional (dexamethasone, melphalan), and novel 
(lenalidomide, perifosine, bortezomib, rapamycin) drugs 
used to treat MM.
RO4987655 (CH4987655) is an allosteric, orally 
available MEK inhibitor developed by Roche/Chiron. It 
has been tested in humans and determined to inhibit active 
ERK levels. At the levels of RO4987655 administered, it 
was determined to be safe in healthy volunteers [90].
TAK-733 is a potent and selective, allosteric MEK 
inhibitor developed by Takeda San Diego [91]. TAK-733 
is being investigated in clinical trials. MEK162 (ARRY-
162) is a MEK inhibitor developed by Novartis. SL337 is 
a MEK inhibitor that has been used in many neurological 
and drug addiction studies [92].
MEK Inhibitors in clinical trials
 There are approximately 84 clinical trials with 
MEK inhibitors listed on the ClinicalTrials.gov website. 
Clinical trials have been and are being performed with 
various cancer patients and selumetinib (AZD6244), 
PD0325901, CI-1040, GSK1120212, TAK-733, 
RO4987655, MEK162, AS703026 and RHEA119. The 
MEK inhibitors may be appropriate for the treatment of 
certain melanomas which have mutant BRAF [62,93]. 
Phase II and III clinical trials have also been performed 
with the allosteric MEK inhibitor GSK1120212 
(trametinib). GSK1120212 is in at least 27 clinical trials. 
NCT01037127 is a phase II clinical trial to examine 
the effectiveness of GSK112012 in melanoma patients 
containing a mutant BRAF gene. The trial will examine the 
effects of GSK112012 in either treatment-naïve or B-Raf 
inhibitor-treated patients. ARRY-438162 (MEK162) is a 
MEK inhibitor is currently in clinical trials in patients with 
advanced cancer. NCT0017925 is a phase I clinical trial 
with RDEA119 (BAY 86-9766) for patients with advanced 
cancers. NCT00957580 is a clinical trial with AS703026. 
Phase I will evaluate the effects of AS703026 on patients 
advanced hemtopoietic malignancies. Phase II is a 
continuation of the trial with AS703026 for elderly AML 
patients who are not good candidates for chemotherapy. 
The effects of MEK inhibitors on on patients with other 
cancers are also being examined in clinical trials. 
Selumetinib is an orally-active MEK1 inhibitor that 
has undergone phase II clinical trials. It is one of the first 
MEK1 inhibitors to be evaluated in randomized phase II 
trials [75,93]. Selumetinib has demonstrated significant 
tumor suppressive activity in preclinical models of cancer, 
including melanoma, pancreatic, colon, lung, liver and 
breast cancer. The effects of selumetinib are enhanced 
significantly if the tumor has a mutation that activates the 
Ras/Raf/MEK/ERK signaling pathway. Selumetinib shows 
great promise in the treatment of pancreatic cancers, which 
often have mutations in Ras that can lead to downstream 
Raf/MEK/ERK pathway activation. Due to the frequent 
detection of pancreatic cancer at advanced stages, it may 
be necessary to combine signal transduction inhibitor 
therapy with conventional chemotherapy after surgical 
removal of the pancreatic cancer if possible. There is a 
clinical trial (NCT01222689) combining selumetinib 
and erlotinib (an EGFR inhibitor) in pancreatic cancer 
patients who have failed gemcitabine therapy. There are 
approximately 49 clinical trials with selumetinib listed on 
the Clinical.Trials.gov website. 
There are approximately 84 clinical trials with MEK 
inhibitors listed on the Clinical.Trials.gov webite. There 
are 15 trials with MEK inhibitors and lung cancer, 14 trials 
with MEK inhibitors and pancreatic cancer, 10 trials with 
MEK inhibitors and colon cancers, 4 trials with MEK 
inhibitors and leukemias, 4 trials with MEK inhibitors 
and HCC, 4 trials with MEK inhibitors and brain cancers, 
2 trials with MEK inhibitors and breast cancer and 
interestingly 0 trials with MEK inhibitors and prostate 
cancer. Initial results from clinical trials have not yielded 
overwhelming support for the use of MEK inhibitors as 
a single therapeutic agent in cancer patients who are not 
pre-screened for pre-existing activation of the Ras/Raf/
MEK/ERK pathway [75,76,93]. Indeed, there are 21 
clinical trials listed on the Clinical.Trials.gov website with 
MEK inhibitors and melanoma patients which often have 
mutation of BRAF and hence activation of downstream 
MEK. The proper pre-identification of cancer patients who 
display activation of the Raf/MEK/ERK pathway may be 
necessary for prescribing MEK inhibitors as part of their 
therapy, as we have stated previously that MEK inhibitors 
are cytostatic and not cytotoxic. 
HCC is the 5th most common cancer world-wide 
and there are few current effective therapies [11,80-83]. 
It is the 3rd most common cause of cancer deaths world-
wide and unfortunately it is the first in terms of cancer 
deaths in improvished countries. Targeting activated 
signaling and metabolic pathways have been considered as 
alternative approaches to treat HCC and improve therapy 
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and outcomes [94-99]. 
Human HCC tumors have higher expression and 
enhanced activity of MEK1/2 and ERK1/2 compared 
with adjacent non-neoplastic liver [80]. Over-expression 
of activated MEK1 in HCC HepG2 cells resulted in 
enhanced tumor growth in vivo [81]. Preclinical studies 
have demonstrated the potential of MEK inhibition to 
suppress hepatoma cell proliferation and tumorigenicity 
[13]. Huynh et al. reported that treatment of human HCC 
xenografts with selumetinib blocked ERK1/2 activation, 
reduced in vivo tumor growth, and induced apoptosis 
[13]. Moreover, targeting MEK with PD-0325901 had in 
vivo chemopreventive effects on HCC development in an 
animal model employing TGF-alpha-transgenic mice in 
which liver cancers were induced by diethylnitrosamine 
treatment [82]. Therefore, MEK represents a potential 
therapeutic target for HCC.
dual raf-MEK Inhibitors
Recently a dual B-Raf/Raf-1 and MEK inhibitor 
has been described [100]. RO5126766 is a first-in-class 
dual Raf/MEK inhibitor which allosterically inhibits 
B-Raf, Raf-1 and MEK. RO5126766 has a different 
mode of action than other Raf inhibitors as binds MEK 
and suppresses the phosphorylation of MEK by Raf via 
the formation of a stable Raf:MEK complex. RO5126766 
selectively inhibited Raf and MEK and not any of the 
other 256 kinases in the Ambit KINOME panel. It was 
also show to be effective in suppressing the growth of 
certain human tumors with various combinations of 
mutated and WT KRAS/HRAS and BRAF. This inhibitor 
has been evaluated in a Phase I clinical trail [100]. Three 
partial responses were observed in fifty-two patients. Two 
BRAF-mutant melanoma patients responded and one 
NRAS- mutant melanoma patient responded. In contrast, 
to treatment with certain B-Raf inhibitors there were no 
cases of keratoacanthomas observed which the authors 
postulated was due to co-inhibitor of Raf and MEK. Dual 
Raf/MEK inhibitors may suppress the development of 
inhibitor resistance.
MEK Inhibitor resistance
Some tumors are resistant to MEK inhibitors 
because they contain EGFR, KRAS, PI3KCA or PTEN 
mutations [101-103]. Some cells with EGFR or KRAS 
mutations are resistant to MEK inhibitors as these 
mutant oncoproteins can also activate the Ras/PI3K/Akt/
mTOR pathway. These studies, which were performed in 
vitro with cells lines and in vivo using xenografts, also 
demonstrated that PI3K activation and PTEN inactivation 
were not always equivalent in terms of inhibitor sensitivity. 
The authors suggested that a possible reason for this 
phenomenon could be that PTEN has other functions 
besides the regulation of Akt (e.g., protein phosphatase 
activity). Furthermore these studies demonstrated that the 
combination of MEK and PI3K pathway inhibitors could 
be an effective approach to treat certain cancers that had 
activation of both pathways.
Breast cancer affects nearly 1 in 7 women and is 
a diverse disease for which there is not one specific 
treatment which can be used to treat all patients. In 
addition, breast cancer patients often develop resistance to 
certain treatments such as hormonal, chemo-, radiotherapy 
perhaps due to the presence of CICs. Many genes have 
been implicated in breast cancer and sensitivity to therapy 
(e.g., HER2, EGFR, ER, PIK3CA, BRCA, PTEN, TP53 
and others) [104-108]. In addition, other genetic and 
epigenetic mechanisms have been implicated including 
deregulated expression of many other types of genes 
including tumor suppressors [109-120], cell cycle 
regulatory molecules [121], and more recently miRNA 
have been implicated in breast cancer [122-125]. In 
addition various physiological and genetic events may 
be altered or provoked in breast cancer and contribute 
to tumor progression and metastasis including: EMT 
[126], survival and expansion of CICs [127-130] genomic 
instability [131,132], epigenetic modifications [133,134], 
changes in the tumor microenvironment and stroma [135-
143], angiogenesis [144], and senescence [145,146]. 
Thus there are many different genetic, biochemical and 
physiological processes which involved in breast cancer 
progression and scientists and clinicians have attempted 
to target various events. As we have stated previously, 
MEK is a common site of interaction of various signaling 
pathways, thus the ability to inhibit breast cancer by MEK 
inhibitors has been investigated.    
Breast cancer can be classified into three types: 
luminal breast cancers which are usually ER+ and 
have a relatively good prognosis and response rate to 
hormonal based therapies, HER2+ cancers which have 
a poor prognosis if untreated but are initially responsive 
to herceptin, and basal-like breast cancers which have a 
poor prognosis and lack expression of HER2, estrogen and 
progesterone receptors (referred to as “triple-negative”).
Only certain types of breast cancer are sensitive 
to MEK inhibitors [102,103]. Many basal breast cancers 
express high levels of EGFR which results in activation 
of the Ras/Raf/MEK/ERK cascade. Hoeflich and 
colleagues [103] found that basal cell breast cancers 
expressed a Ras-like expression profile and tested their 
hypothesis that these breast cancers could be sensitive 
to MEK inhibitors, providing that they do not have 
PI3KCA mutations or PTEN deletions. In contrast, many 
luminal and HER2-amplified tumors are resistant to MEK 
inhibitors. They also determined that PTEN loss was a 
negative predictor factor for response to MEK inhibitors. 
Furthermore, treatment with MEK inhibitors often led 
to an increase in activated Akt expression, providing the 
rationale to examine the consequences of co-addition of 
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MEK and PI3K inhibitors. The authors also determined 
that co-administration of MEK and PI3K inhibitors 
enhanced killing of the certain breast cancers. Thus the 
investigations by Wee et al, and Hoeflich et al., have 
demonstrated the concept that elevated PI3K/Akt/mTOR 
expression will confer resistance to MEK inhibitors. 
These studies illuminate the critical role of genetics in 
determining the sensitivity to targeted therapy.
Other studies have also indicated that some tumors 
with EGFR mutations are resistant to MEK inhibitors. 
Mutations at the BRAF, KRAS, EGFR genes or the 
chromosomal fusion between anaplastic lymphoma kinase 
(ALK) and ROS (oncogene that belongs to the sevenless 
subfamily of tyrosine kinase insulin receptor genes, 
originally detect in the v-ros retrovirus)  tyrosine kinases 
are detected in approximately 50% of NSCLC. NSCLC 
cells with BRAF mutations where shown to be more 
sensitive to MEK inhibitors than NSCLC with mutations 
in EGFR, KRAS, or the chimeric fusion between ALK 
and ROS [101]. This was determined by screening a 
large panel of cell lines (n=87) and tumors (n=916). In 
this study, cells with mutations at EGFR were resistant to 
MEK inhibitors. This may have resulted from the ability 
of EGFR to activate the PI3K/PTEN/Akt/mTOR pathway 
which as discussed below has some crucial overlapping 
targets with the Raf/MEK/ERK pathway. NSCLC patients 
with EGFR mutations should not be treated with MEK 
(or BRAF) inhibitors as the respective therapies would be 
ineffectual. 
In some MEK inhibitor-resistant melanoma cells 
which contained either the G469E or D594G mutant 
BRAF alleles, activation of Raf-1 by the mutant B-Raf 
proteins was observed to confer resistance to MEK 
inhibitors [18]. The G469E and D594G BRAF mutants are 
considered weak B-Raf mutations and signal through Raf-
1. In these cells, survival is mediated by the G469E- and 
D594G-mutant B-Raf proteins stimulating Raf-1 which 
becomes mitochondrial localized and regulates apoptosis 
though phosphorylation of Bad and enhancement of the 
anti-apoptotic properties of Bcl-2. Sorafenib induced a 
reduction of Bad phosphorylation and Bcl-2 expression in 
the D594G/G469E melanoma cells. The effects of Raf-1 
on the prevention of apoptosis were demonstrated in the 
D594G/G469E but not BRAF V600E mutant melanoma 
cells by shRNA knock down of Raf-1. These studies 
indicate that sorafenib may be appropriate in the treatment 
of a minority of melanomas which survive in response 
to Raf-1 activation and are essentially MEK inhibitor-
resistant.
Amplification of a mutant BRAF gene in 
selumetinib-resistant CRCs was observed in cells which 
were selected for selumetinib-resistance in vitro [65]. 
The sensitivity of the cells to the MEK inhibitor could be 
restored by treatment with low doses of a B-Raf inhibitor. 
In this study, the authors demonstrated that the amplified 
mutant BRAF gene was present in a small minority of 
treatment-naïve cells. In another study by a different group 
of investigators, resistance to selumetinib was observed 
in CRC lines harboring mutations in BRAF (COLO205 
and HT29) or KRAS (HCT116, LoVo). The selumetinib-
resistant lines did not appear to have mutations in either 
MEK1 or MEK2 but had upregulation of B-Raf or K-Ras 
respectively due to intrachromosomal amplification of 
their respective driving oncogenes, BRAF V600E or KRAS 
G13D which the authors demonstrated was responsible for 
their selumetinib-resistance [147,148].  
Mutations in the allosteric binding pocket of the 
MEK1 gene were observed in a different study which 
isolated MEK-inhibitor resistant cells from MDA-
MB-231 basal breast cancer cells [149]. Basal breast 
cancer cells are often sensitivity to MEK inhibitors. The 
MDA-MB-231 cell line has mutations at BRAF G464V 
and KRAS G13D. The MEK inhibitor-resistance could be 
overcome by treatment with ERK inhibitors, even in the 
resistant cell line with KRAS amplification. 
Additional MEK-inhibitor resistant lines were 
derived from HCT-116 and LoVo CRC cell lines [149]. 
The MEK inhibitor-resistant HCT-116 cell line also had 
mutations in the allosteric binding pocket mutations in 
MEK1 while the MEK inhibitor-resistant LoVo cells had 
mutations in the allosteric binding pocket in MEK2. One 
MEK inhibitor-resistant HCT-116 cell line also had the 
allosteric binding pocket mutation as well as amplification 
of KRAS but remained sensitive to growth inhibition upon 
treatment with the ATP-competitive ERK inhibitor, ERKi 
(name of inhibitor provided by authors in manuscript). 
These studies also demonstrated the effectiveness of 
inhibiting ERK in overcoming resistance to MEK 
inhibitors even if BRAF or KRAS is amplified or mutated. 
Furthermore the combination of MEK and ERK inhibitors 
may be beneficial in treating certain inhibitor-resistant 
cells. 
combining raf and MEK Inhibitors
 The possibility of treating certain patients with a 
Raf and a MEK inhibitors is a concept which is gaining 
more acceptance as it may be a therapeutic possibility 
to overcome resistance [14]. Raf inhibitors induce Raf 
activity in cells with WT RAF if Ras is active, however, 
the addition of a MEK inhibitor would suppress the 
activation of MEK and ERK in the normal cells of the 
cancer patient. Thus B-Raf would be suppressed by the 
B-Raf-selective inhibitor in the cancer patient while the 
consequences of Raf activation in the normal cells would 
be suppressed by the MEK inhibitor. These concepts are 
being examined in clinical trials (NCT01072175 and 
NCT01231594). NCT01072175 is a clinical trial with 
the Raf inhibitor GSK2118436 in combination with the 
MEK Inhibitor GSK1120212 in metastatic melanoma 
patients containing mutant BRAF gene. NCT01352273 is 
a clinical trial with combinations of MEK162 and RAF265 
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examining the effects these MEK and Raf inhibitors 
on adult patients with solid tumors with either RAS or 
BRAF V600E mutations. The MEK inhibitor RDEA119/
refametinib and sorafenib have been combined in Phase 
I/II clinical trials (NCT00785226) with patients having 
various types of advanced cancer. The dual Raf/MEK 
inhibitor RO5126766 has been in Phase I clinical trials 
[100]. 
The effects of combining MEK and Bcl-2/Bcl-XL 
inhibitors have been examined in pre-clincial studies with 
AML cell lines and patient samples [150]. The Bcl-2/
Bcl-XL inhibitor ABT-737 was observed to induce ERK 
activation and Mcl-1 expression. However, when the 
ABT-737 inhibitor was combined with the MEK inhibitor 
PD0325901, a synergistic response was observed in terms 
of the induction of cell death both in AML cell lines and 
primary tumor cells with the properties of leukemia stem 
cells (a.k.a. CICs). Furthermore these studies were also 
extended into tumor transplant models with the MOLT-13 
cell line and synergy between ABT-737 and PD0325901 
were also observed in vivo.    
ErK Inhibitors
There are at least two ERK molecules regulated by 
the Raf/MEK/ERK cascade, ERK1 and ERK2. Little is 
known about the differential in vivo targets of ERK1 and 
ERK2. The development of specific ERK1 and ERK2 
inhibitors is ongoing and may be useful in the treatment 
of certain diseases such as those leukemias where elevated 
ERK activation is associated with a poor prognosis (e.g., 
AML, ALL) [151]. ERK inhibitors have been described 
[152]. AEZS-131 has been reported on the internet to be a 
highly selective ERK 1/2 inhibitor developed by AEterna 
Zentaris. Other ERK inhibitors (ERKi) have also been 
developed and evaluated for their use in overcoming MEK 
inhibitor resistance [149]. 
Inhibitors targeting the PI3K/Akt/mtor 
Pathway 
Numerous PI3K inhibitors have been developed 
and evaluated [3,4,6-10]. These include: LY-294002 
(Lilly), Wortmannin, PX-866 (Oncothyreon), GDC-0941 
(Genentech), CAL-101 (Calistoga Pharmaceuticals), 
XL-147 and XL-765 (Exelixis and Sanofi-Aventis). 
Some PDK1 inhibitors have been described but they 
are not specific for PDK1 including OSU-03012 
(Arno Therapeutics) and Celecoxib (Pfizer). Various 
Akt inhibitors have been developed [153-157]. These 
include: A-443654 (Abbott Laboratories), GSK690693 
(GlaxoSmithKline), VQD-002 (a.k.a. API-2, VioQuest 
Pharmaceuticals), KP372-1 (QLT, Inc), perifosine 
(AEterna Zentaris/Keryx Biopharmaceuticals) and MK-
2206 (Merck). Inhibitors of downstream mTOR have been 
evaluated [158-161]. These include: rapamycin (Wyeth-
Pfizer, sirolimus) and modified rapamycins (rapalogs) 
(CCI-779, torisel, temsirolimus, Wyeth-Pfizer), AP-23573 
(ridaforolimus, Ariad-Merck) and RAD001 (afinitor, 
everolimus, Novartis). Rapamycin and the modified 
rapalogs are mTORC1 inhibitors. A diagram illustrating 
the sites of action of various inhibitors is presented in 
Figure 3.
PI3K Inhibitors
Two well-known and isoform-nonselective PI3K 
inhibitors are the fungal metabolite wortmannin and 
LY294002. These drugs block the enzymatic activity 
of PI3K by different mechanisms. Wortmannin is an 
irreversible inhibitor (IC50≈2 nM) which forms a covalent 
bond with a conserved lysine residue involved in the 
phosphate-binding reaction [162], while LY294002 is a 
classical reversible, ATP-competitive PI3K modulator 
(IC50=1.40 μM) [163].
In spite of the crossover inhibition of other 
lipid and protein kinases (for example, LY294002 
also inhibits mTOR, casein kinase 2 (CK2), DNA-
dependent protein kinase (DNA-PK) and others) [164], 
and their unfavorable pharmaceutical properties, both 
wortmannin and LY294002 have served as important 
research tools for more than a decade in elucidating the 
role of PI3K in the biology of human cancer [165-170]. 
The modified wortmannin, PX-866 is a PI3K inhibitor 
[171,172]. It has been evaluated in Phase I clinical trials. 
PX-866 is currently being evaluated in approximately 
five clinical trials for prostate cancer, melanoma, CRC, 
NSCLC, squamous cell carcinoma of the head and neck, 
glioblastoma and other advanced cancers. 
GDC-0941 is a PI3K inhibitor developed 
by Genentech. GDC-0941 inhibited the metastatic 
characteristics of thyroid carcinomas by targeting both 
PI3K and hypoxia-inducible factor-1alpha (HIF-1-alpha) 
pathways [173]. GDC-0941 synergized with the MEK 
inhibitor UO126 in inhibiting the growth of NSCLC 
[174]. It is being evaluated in a clinical trial for advanced 
cancers or metastatic breast cancers which are resistant to 
aromatase inhibitor therapy (NCT01437566). 
IC87114 is a selective p110-delta PI3K inhibitor. It 
decreased cell proliferation and survival in AML cells, and 
increased sensitivity to etoposide [175-179]. It has been 
in clinical trials to treat AML patients (NCT00004263 
and NCT00301938). CAL-101(GS-1101) is a derivative 
of IC-87114 [180-184]. It is an oral p110-delta PI3K 
inhibitor developed by Calistoga Pharmaceuticals and 
Gilead Sciences. CAL-101 is currently undergoing 
clinical evaluation in patients with various hematopoietic 
malignancies including: relapsed or refractory indolent 
B-cell NHL, mantle cell lymphoma or CLL. An additional 
clinical trial, will examine the effects of combining 
CAL-101 with chemotherapeutic drugs and the αCD20 
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monoclonal Ab (MoAb). The clinical trial (NCT01088048) 
will examine the effects of combining CAL-101 with 
chemotherapeutic drugs and the αCD20 monoclonal Ab. 
CAL-101 has displayed significant cytotoxic activity in 
23% of B-ALL samples tested, but only in 3% of AML 
samples. CAL-101 treatment resulted in dephosphorylated 
Akt-1 at T308 and induced apoptosis in neoplastic B-cells 
[181]. Remarkably, CAL-101 did not significantly affect 
the survival of healthy B-, T-, and natural killer (NK) 
lymphocytes [182]. However, it was found that CAL-
101 inhibited the production of inflammatory cytokines, 
such as interleukin-6 (IL-6), IL-10, tumor necrosis factor 
(TNF)-alpha (produced by T-lymphocytes), and interferon 
(IFN)-gamma (synthesized by NK lymphocytes). It 
remains to be established whether decreased production 
of TNF-alpha and IFN-gamma will impair inflammatory 
responses in B-ALL patients treated with CAL-101. 
XL-147 (SAR245408) is a PI3K inhibitor developed 
by Exelixis/Sanofi-Aventis [183]. 2010). It is in at least 11 
clinical trials, either as a single agent or in combination 
with erlotinib, hormonal therapy, chemotherapy, or MoAb 
therapy for various cancers including: lymphoma, breast, 
endometrial, glioblastoma, astrocytoma or other solid 
cancers. 
NVP-BKM120 (BKM120) is an orally available 
pan-class I PI3K inhibitor developed by Novartis 
[184,185]. It is in clinical trials, either as a single agent 
or in combination with other drugs or signal transduction 
inhibitors [185]. NVP-BKM120 is in at least 36 clinical 
trials with patients having advanced cancers such as CRC, 
NSCLC, breast, prostate, endometrial, squamous cell 
carcinoma of the head and neck, GIST, RCC, melanoma 
and advanced leukemias. 
NVP-BYL719 (BYL719) is a PI3K-alpha selective 
inhibitor developed by Novartis. It is in clinical trials for 
patients with advanced solid tumors (NCT01387321) 
some containing mutations at PIK3CA (NCT01219699). 
It is also being examined in a clinical trial in combination 
with the MEK-162 inhibitor for patients with advanced 
CRC, esophageal, pancreatic, NSCLC or other advanced 
solid tumors containing RAS or BRAF mutations 
(NCT01449058). Some have questioned whether 
inhibitors which target just PI3K will be effective in cancer 
therapy as single agents due to in part the complicated 
feed-back loops which result in the activation of certain 
receptor molecules [186]. 
dual PI3K/mtor Inhibitors
The catalytic sites of PI3K and mTOR share a high 
degree of sequence homology. This feature has allowed the 
synthesis of ATP-competitive compounds that target the 
catalytic site of both PI3K and mTOR. Several dual PI3K/
mTOR inhibitors have been developed. In preclinical 
settings, dual PI3K/mTOR inhibitors displayed a much 
stronger cytotoxicity against leukemic cells than either 
PI3K inhibitors or allosteric mTOR inhibitors, such as 
rapamycin or rapalogs. In contrast to rapamycin/rapalogs, 
dual PI3K/mTOR inhibitors targeted both mTOR complex 
1 and mTOR complex 2, and inhibited the rapamycin-
resistant phosphorylation of eIF4B-1 and inhibited 
protein translation of many gene products associated with 
oncogenesis (enhanced proliferation) in leukemic cells. 
The dual inhibitors strongly reduced the proliferation rate 
and induced an important apoptotic response [7]. 
The kinase selectivity profile of the dual PI3K/
mTOR modulators is consistent with the high sequence 
homology and identity in the ATP-catalytic cleft of these 
kinases. Dual PI3K/mTOR inhibitors have demonstrated 
significant, concentration-dependent cell proliferation 
inhibition and induction of apoptosis in a broad panel 
of tumor cell lines, including those harboring PIK3CA 
activating mutations [187].
Moreover, the in vitro activity of these ATP-
competitive PI3K/mTOR modulators has translated well in 
in vivo models of human cancer xenografted in mice. They 
were well tolerated and achieved disease stasis or even 
tumor regression when administered orally [188]. In spite 
of their high lipophilicity and limited water solubility, the 
pharmacological, biological and preclinical safety profiles 
of these dual PI3K/mTOR inhibitors supported their 
clinical development [189]. 
There may be some benefits to treating patients 
with an inhibitor that can target both PI3K and mTOR 
as opposed to treating patients with two inhibitors, i.e., 
one targeting PI3K and another specifically mTOR. An 
obvious benefit could be lowered toxicities. Treatment 
with a single drug could have fewer side effects than 
treatment with two separate drugs. The effects of 
detrimental Akt activation by mTOR inhibition might 
be avoided upon treatment with a dual kinase inhibitor. 
Furthermore, the negative side effects of mTOR inhibition 
on the activation of the Raf/MEK/ERK pathway might 
be eliminated with the PI3K inhibitor activity in the 
dual inhibitor. There remains, however, considerable 
uncertainty about potential toxicity of compounds that 
inhibit both PI3K and mTOR enzymes whose activities 
are fundamental to a broad range of physiological 
processes. Although it should be pointed out that there are 
some clinical trials in progress to determine whether it is 
beneficial to treat cancer patients with a PI3K/mTOR dual 
inhibitor and an mTORC1 blocker such as NVP-BEZ235 
and RAD001. Pre-clinical studies have documented the 
benefits of combining RAD001 with NVP-BEZ235 [190].
PI-103 was the first reported ATP-competitive kinase 
inhibitor of mTOR which also blocked the enzymatic 
activity of PI3K p110 isoforms. It was developed at UCSF 
in 2006. PI-103 exhibits good selectivity over the rest of 
the human kinome in terms of non-selective inhibition 
of other kinases [191,192]. PI-103 is a pan-class I PI3K 
inhibitor with IC50 values in the 2 nM (p110-alpha PI3K) 
to 15 nM range (p110-gamma PI3K) PI-103 inhibits both 
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mTORC1 (IC50=0.02 microM) and mTORC2 (IC50=0.083 
microM).  
NVP-BEZ235 is a dual PI3K/mTOR inhibitor 
developed by Novartis. Importantly and in contrast to 
rapamycin, NVP-BEZ235 inhibited the rapamycin-
resistant phosphorylation of 4E-BP1, causing a marked 
inhibition of protein translation in AML cells. This 
resulted in reduced levels of the expression of c-Myc, 
cyclin D1, and Bcl-xL known to be regulated at the 
translation initiation level [193]. NVP-BEZ235 suppressed 
proliferation and induced an important apoptotic 
response in AML cells without affecting healthy CD34+ 
cell survival. Importantly, it suppressed the clonogenic 
activity of leukemic, but not healthy, CD34+ cells [194]. 
NVP-BEZ235 targeted the side population (SP) of 
both T-ALL cell lines and patient lymphoblasts, which 
might correspond to CICs, and synergized with several 
chemotherapeutic agents (cyclophosphamide, cytarabine, 
dexamethasone) currently used for treating T-ALL patients 
[195]. Also, NVP-BEZ235 reduced chemoresistance 
to vincristine induced in Jurkat cells by co-culturing 
with MS-5 stromal cells, which mimic the bone marrow 
microenvironment [196]. In this study, NVP-BEZ235 
was cytotoxic to T-ALL patient lymphoblasts displaying 
pathway activation, where the drug dephosphorylated 4E-
BP1, in contrast to the results obtained with rapamycin. 
Taken together, these findings indicated that longitudinal 
inhibition at two nodes of the PI3K/Akt/mTOR network 
with NVP-BEZ235, either alone or in combination with 
chemotherapeutic drugs, may be an effective therapy for 
of those T-ALLs that have aberrant upregulation of this 
signaling pathway.
NVP-BEZ235 has been evaluated also in a mouse 
model consisting of BA/F3 cells overexpressing either 
WT BCR-ABL or its imatinib-resistant BCR-ABL mutants 
(E255K and T315I) [197]. NVP-BEZ235 inhibited 
proliferation of both cytokine-independent WT BCR-ABL 
and mutant BCR-ABL (E255K and T315I) overexpressing 
cells, whereas parental cytokine-dependent Ba/F3 cells 
were much less sensitive. The drug also induced apoptosis, 
and inhibited both mTORC1 and mTORC2 signaling. 
Remarkably the drug displayed cytotoxic activity in vivo 
against leukemic cells expressing the E255K and T315I 
BCRABL mutant forms However, in this experimental 
model, NVP-BEZ235 induced an over activation of 
MEK/ERK signaling, most likely due to the well-known 
compensatory feedback mechanism that involves p70S6K 
[198]. NVP-BEZ235 has been intensively investigated 
and is in at least eight clinical trials for patients with 
advanced cancers [199]. NCT01343498, NCT01195376 
and NCT01513356 are clinical trials of NVP-BEZ235 
as a single agent in patients with advanced solid tumors 
including breast. In the clinical trial NCT00620594, NVP-
BEZ235 is being evaluated in breast cancer patients, 
some of whom may also be treated with herceptin. 
NCT01285466 is a clinical trial for patients with advanced 
solid cancers who will be treated with NVP-BEZ235, 
paclitaxel and herceptin. NVP-BTG226 is a recently 
developed PI3K/mTOR inhibitor by Novartis. 
PKI-587 is a PI3K/mTOR inhibitor developed by 
Pfizer [201,202]. It is also known as PF-05212384 and it 
inhibits class I PI3Ks, PI3K-alpha mutants, and mTOR. 
PKI-587 suppressed proliferation of approximately 50 
diverse human tumor cell lines with IC50 values less than 
100 nmol/L. PKI-587 induced apoptosis in cell lines with 
elevated PI3K/Akt/mTOR signaling. PKI-587 inhibited 
the tumor growth in various models including: breast 
(MDA-MB-361, BT474), colon (HCT116), lung (H1975), 
and glioma (U87MG). The efficacy of PKI-587 efficacy 
was enhanced when administered in combination with the 
MEK inhibitor, PD0325901, the topoisomerase I inhibitor, 
irinotecan, or the HER2 inhibitor, neratinib.  
PF-04691502 is an ATP competitive PI3K/Akt 
inhibitor developed by Pfizer which suppresses activation 
of Akt [202]. PF-04691502 suppressed transformation of 
avian cells in response to either WT or mutant PIK3CA. 
PF-04691502 inhibited tumor growth in various xenograft 
models including U87 (PTEN null), SKOV3 (PIK3CA 
mutant), and gefitinib (EGFR inhibitor) and erlotinib-
resistant NSCLC [202].  Both PKI-587 and PF-04691502 
are in clinical trials with patients having endometrial 
cancers (NCT01420081). 
PKI-402 is a selective, reversible, ATP-competitive, 
PI3K and mTOR inhibitor developed by Pfizer. It 
suppresses mutant PI3K-alpha and mTOR equally. PKI-
402 inhibited the growth of many human tumor cell lines 
including: breast, glioma, pancreatic, and NSCLC [203]. 
XL765 (SAR25409) is a dual PI3K/mTOR inhibitor 
developed by Exelixis/Sanofi-Aventis. XL765 has been 
investigated in brain and pancreatic cancer models either 
as a single agent or in combination with temozolomide 
[204] or the autophagy inhibitor chloroquine [205]. 
XL765, downregulated the phosphorylation of Akt induced 
by PI3K/mTORC2 and reduced brain tumor growth 
[204]. Combining XL765 with chloroquine suppressed 
autophagy and induced apoptotic cell death in pancreatic 
tumor models [205]. XL-147 (SAR245408) and XL-765 
(SAR245409) are in at least 13 clinical trials, either as a 
single agent or in combination with erlotinib, hormonal 
therapy, chemotherapy, or MoAb therapy for various 
cancers including: lymphoma, breast, endometrial or other 
solid cancers. NCT01240460 is a clinical trial for recurrent 
glioblastoma and astrocytoma grade IV patients who are 
candidates for surgical resection by Exelixis and Sanofi-
Aventis.  XL765 (Exelixis/Sanofi-Aventis) [204] has been 
in clinical trials either as single agent (NCT00485719) to 
treat patients with advanced tumors.  In one study XL765, 
downregulated the phosphorylation of Akt induced by 
PI3K/mTORC2 and reduced tumor growth. XL765 also 
resulted in clinical benefit in 5 out of 19 patients [188]. 
Other clinical trials are being performed with XL765 in 
combination with temozolomide to treat patients with 
Oncotarget 2012; 3: 1068-11111085www.impactjournals.com/oncotarget
glioblastoma (NCT00704080) or in combination with 
erlotinib to treat NSCLC patients (NCT00777699).
GNE-477 is a dual PI3K/mTOR inhibitor developed 
by Genentech. GDC-0980 is similar to GNE-477 and has 
high activity in cancer models driven by PI3K pathway 
activation [206]. GDC-0980 is in a clinical trial for 
patients with advanced cancers or metastatic breast 
cancers which are resistant to aromatase inhibitor therapy 
(NCT01437566).
GSK2126458 is a dual PI3K/mTOR inhibitor 
developed by GSK [80]. It is in at least two clinical 
trials with advanced cancer patients. In one trial it is 
being combined with the MEK inhibitor GSK1120212. 
GSK1059615 is a dual PI3K/mTOR inhibitor developed 
by GSK. It was in a clinical trial with patients with solid 
tumors, metastatic breast cancer, endometrial cancers and 
lymphomas which was terminated.
WJD008 (Chinese Academy of Sciences, Shanghai) 
is a dual PI3K/mTOR [207]. WJD008 inhibited the 
increased activity of the PI3K pathway normally induced 
by PIK3CA H1047R and suppressed proliferation and 
colony formation of transformed RK3E cells containing 
PIK3CA H1047R.
resistance to PI3K/mtor Inhibitors
Recently resistance to PI3K/mTOR inhibitors has 
been observed. In one case, c-Myc and eIF4E amplification 
were observed which result in elevated 5’cap-dependent 
protein translation in human mammary epithelial cells that 
were resistant to NVP-BEZ235 [208]. In another study, the 
authors observed NOTCH pathway, including downstream 
c-Myc activation which eliminated the dependency of the 
cells on the PI3K/Akt/mTOR pathway [209]. NOTCH is 
frequently activated in T-ALL [6-10]. This may explain 
the resistance of some ALLs to PI3K inhibitors.  c-Myc 
is frequently amplified in certain cancers [3-6]. This may 
contribute to the inherent resistance of this type of tumor 
to PI3K inhibitors [209]. A diagram illustrating potential 
mechanisms of resistance to PI3K/mTOR inhibitors is 
presented in Figure 4.
PdK Inhibitors
Some compounds have been reported to be PDK 
inhibitors, including the modified celecoxib, OSU-
03012 [210, 211] and 2-O-BN-InsP(5) [212]. Celecoxib 
(Celebrex, Pfizer) obviously has other targets than PDK, 
such as cyclooxygenase-2 (Cox-2). Celecoxib is used to 
treat CRC patients to reduce the number of polyps in the 
colon. OSU-03012 is reported not to inhibit Cox-2 [210]. 
2-O-BN-InsP(5) is based on the structure of based on the 
structure of inositol 1,3,4,5,6-pentakisphosphate, it may 
inhibit both PDK and mTOR [212].
Akt Inhibitors
Many attempts to develop Akt inhibitors have been 
performed over the years. In many of the earlier attempts, 
the various Akt inhibitors either lacked specificity or 
had deleterious side effects. Part of their deleterious side 
effects of many “Akt” inhibitors are probably related to 
the numerous critical functions that Akt plays in normal 
physiology. Namely some Akt inhibitors will alter the 
downstream effects of insulin on Glut-4 translocation and 
glucose transport.
Triciribine (API-2) is an Akt inhibitor that has 
been used in many studies; at least 92 are listed on 
the ClinicalTrials.gov website. Triciribine suppressed 
phosphorylation of all three Akt isoforms in vitro and 
the growth of tumor cells overexpressing Akt in mouse 
xenograft models [213]. The mechanism(s) by which 
triciribine inhibits Akt activity are not clear. The drug 
has been evaluated in a phase I clinical trial in patients 
with advanced hematologic malignancies, including 
refractory/relapsed AML. In this trial (NCT00642031), 
triciribine was administered on a weekly schedule. The 
drug was well-tolerated, with preliminary evidence of 
pharmacodynamic activity as measured by decreased 
levels of activated Akt in primary blast cells [214]. 
Triciribine has also been examined in a clinical trial 
(NCT00363454) with Akt+ metastatic cancers.
MK-2206 (Merck) is an allosteric Akt inhibitor 
which inhibits both T308 and S473 phosphorylation. It 
also inhibits the downstream effects of insulin on Glut-
4 translocation and glucose transport [215]. MK-2206 
decreased T-acute lymphocytic leukemia (T-ALL) cell 
viability by the blocking the cells in the G0/G1 phase of 
the cell cycle and inducing apoptosis. MK-2206 also 
induced autophagy in the T-ALL cells. MK-2206 induced 
a concentration-dependent dephosphorylation of Akt and 
its downstream targets, GSK-3-alpha/beta and FOXO3A. 
MK-2206 also was cytotoxic to primary T-ALL cells and 
induced apoptosis in a T-ALL patient cell subset (CD34+/
CD4-/CD7-) which is enriched in CICs. [216]. MK-2206 
is in at least 43 clinical trials either as a single agent or 
in combination with other small molecule inhibitors or 
chemotherapeutic drugs with diverse types of cancer 
patients.
GSK690693 is a pan Akt inhibitor developed 
by GSK. GSK690693 is an ATP-competitive inhibitor 
effective at the low-nanomolar range. Daily administration 
of GSK690693 resulted in significant antitumor activity 
in mice bearing various human tumor models including 
SKOV-3 ovarian, LNCaP prostate, and BT474 and HCC-
1954 breast carcinoma. The authors also noted that 
GSK690693 resulted in acute and transient increases in 
blood glucose level [217]. The effects of GSK690693 
were also examined in 112 cell lines representing different 
hematologic neoplasia. Over 50% of the cell lines were 
sensitive to the Akt inhibitor with an EC50 of less than 
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1 µM. ALL, non-Hodgkin lymphomas, and Burkitt 
lymphomas exhibited 89%, 73%, and 67% sensitivity 
to GSK690693, respectively. Importantly GSK690693 
did not inhibit the proliferation of normal human CD4+ 
peripheral T lymphocytes as well as mouse thymocytes.
GSK2141795 is an Akt inhibitor under development 
at GSK. It is reported by GSK to be an oral, pan Akt 
inhibitor which shows activity in various cancer models, 
including blood cancers and solid tumor models. In 
addition it is reported by GSK to delay tumor growth 
in solid tumor mouse xenograft models. It has been 
investigated further in clinical trials.
KP372-1 (QLT, Vancouver, Canada) inhibits PDK1, 
Akt and Fms-like tyrosine kinase 3 (Flt-3) signaling 
and induces mitochondrial dysfunction and apoptosis in 
AML cells but not normal hematopoietic progenitor cells 
[218]. It also suppressed colony formation of primary 
AML patient sample cells but not normal hematopoietic 
progenitor cells.  It has also been investigated in other 
cancer types, including squamous cell carcinomas of the 
head and neck, thyroid cancers and glioblastomas.
Enzasturin (LY317615) is a protein kinase C-beta 
(PKC-beta) and Akt inhibitor developed by Lilly. It has 
been investigated in clinical trials either by itself or in 
combination with other agents in various types of cancer 
patients including: brain [219] and NSCLC [220], CRC 
[221] as well as other cancer types. It is reported to be in 
approximately 48 clinical trials on the ClinicalTrials.gov 
website.
Perifosine (KRX-0401, Keryx / AOI 
Pharmaceuticals, Inc. and licensed to AEterna Zentaris) is 
an alkylphospholipid that can inhibit Akt [222]. The effects 
of perifosine have been examined on many different tumor 
types. Perifosine induces caspase-dependent apoptosis and 
downregulates P-glycoprotein expression in multidrug-
resistant T-ALL cells by a JNK-dependent mechanism 
[223]. Perifosine is or has been in at least 43 clinical trials 
to treat various cancer patients, with either blood cancers 
or solid tumors, either by itself, or in combination with 
other agents. It has advanced to phase III clinical trials for 
CRC and MM. In the USA it has orphan drug status for the 
treatment of MM and neuroblastoma.
Erucylphosphocholine (ErPC) and 
erucylphosphohomocholine (ErPC3) have been shown 
to inhibit Akt and induce apoptosis in malignant glioma 
cell lines which are normally resistant to the induction 
of apoptosis. They are structurally related to perifosine 
[224]. ErPC enhanced radiation-induced cell death and 
clonogenicity [225]. These effects on the induction of 
apoptosis were correlated with increased Bim levels and 
decreased Bad and Foxo-3 phosphorylation, potentially 
consequences of decreased Akt activity. ErPC3 is the first 
intravenously applicable alkylphosphocholine. ErPC3 was 
cytotoxic to AML cells through JNK2- and PP2-dependent 
mechanisms [226].
PBI-05204 (oleandrin) is an Akt inhibitor. PBI-
05024 is a botanical drug candidate derived from Nerium 
oleander and developed by Phoenix Biotechnology.  It 
also has other targets including FGF-2, NF-kappaB, and 
p70S6K.  PBI-05204 is in clinical trials for cancer patients 
with advanced solid tumors [227]. Interesting PBI-05204 
also provides significant neuroprotection to tissues 
damaged by glucose and oxygen deprivation which occurs 
in ischemic stroke [228].
RX-0201 (Akt1AO, Rexahn Pharmaceuticals, 
Inc.) is an Akt-1 anti-sense oligonucleotide molecule. 
RX-0201 downregulated Akt-1 expression at nanomolar 
concentrations in multiple types of human cancer. RX-
0201 also inhibited tumor growth in mice xenografted with 
U251 human glioblastoma and MIA human pancreatic 
cancer cells [229]. RX-021 has been in a clinical trial in 
combination with gemcitabine for patients with metastatic 
pancreatic cancer [230].  
XL-418 is reported to be a dual Akt/p70S6K 
inhibitor by developed by Exelixis/GSK.  It was in clinical 
trials for patients with advanced cancer, however those 
trials were suspended.
mtorc1 Inhibitors 
Rapamycin (Rapamune, Pfizer) was approved by 
the FDA in 1999 to prevent rejection in organ transplant 
patients. Rapamycin/rapalogs act as allosteric mTORC1 
inhibitors and do not directly affect the mTOR catalytic 
site [6,7]. They associate with the FK506 binding protein 
12 (FKBP-12) and by so doing, they induce disassembly of 
mTORC1, resulting in repression of its activity [231,232]. 
The rapalogs have been examined in clinical trials with 
patients having various cancers including: brain, breast, 
HCC, leukemia, lymphoma, MM, NSCLC, pancreatic, 
prostate, and RCC [233, 234]. Furthermore rapamycins 
are being considered as anti-aging and anti-obestity drugs 
as well as to prevent diabetic neuropathy [236-239]. 
The rapalogs torisel (Pfizer) amd afinitor (Novartis) 
were approved in 2007 and 2009 (respectively) to treat 
RCC patients [240]. In 2008, torisel was approved to treat 
Mantel cell lymphoma patients. In 2010, Afinitor was 
approved to treat subependymal giant cell astrocytoma 
(SEGA) tumors in tuberous sclerosis (TS) patients. 
In 2011, Afinitor was approved to treat patients with 
pancreatic neuroendocrine tumors [241]. 
Ridaforolimus (also known as AP23573 and MK-
8669; formerly known as deforolimus) is a rapalog 
developed by ARIAD and Merck. Ridaforolimus has 
been evaluated in clinical trials with patients having 
metastatic soft-tissue or bone sarcomas where it displays 
promising results in terms of the risk of progression or 
death [242]. Recently the ability of rapamycin and rapalog 
to treat various viral infections including AIDS has been 
considered [243,244]. Clearly rapamycin has proven to be 
a very useful drug.  In addition, novel approaches to target 
mTORC have been developed (see below).
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sensitivity to rapamycin
 Multiple mechanisms have been described to be 
responsible for sensitivity to rapamycin [245]. Rapamycin 
sensitivity has been associated with PTEN mutation/
silencing (inactivation), PIK3CA mutation (activation) 
and Akt hyperactivation. RCC patients are hypersensitive 
to rapalogs as they often have loss of function of the 
von-Hippel-Lindau (VHL) tumor suppressor gene which 
is an E3 ubiquitin ligase that promotes the proteasomal 
degradation of HIF-1-alpha and HIF-1-beta [246]. 
Rapalogs promote reduction of HIF-1-alpha levels, thus 
RCC cells can not survive and are hyper-sensitive to 
rapalogs [247].  Mantel cell lymphoma grown in part due 
to increased levels of cyclin D1. mTOR inhibitors suppress 
cyclin D1 mRNA translation, thus Mantel cell lymphomas 
are hypersensitive to rapalogs [248]. Inhibition of IGF-1R 
signaling increases sensitivity to mTOR inhibitors. 
resistance to rapamycin/rapalogs
 Resistance to rapamycin has been associated with 
KRAS or BRAF mutations. Since KRAS is frequently 
mutated in human cancer, many cancers will have 
constitutive mTOR activity, but may not be sensitive to 
rapamycin as they will have Raf/MEK/ERK pathway 
activation. Since rapalogs function by binding FKBP-12, 
mutations in FKBP12 or the FKB domain of mTOR can 
suppress binding affinity and lead to rapalog resistance 
[245,249-251]. Direct mTOR inhibitors will overcome 
this resistance. The presence of the IGF1R/PI3K-mediated 
feedback loop, which results in ERK activation, is another 
mechanism of resistance to rapamycin rapalogs [3,4,6-10].
Up regulation of the PIM kinases is another 
mechanism of resistance to rapalogs [252]. The PIM 
family of oncogenic serine/threonine kinases play 
important roles in the regulation of cell growth [253,254] 
Pim kinases have multiple substrates important in the 
regulation of cell growth including: c-Myc, p27, dual 
specificity phosphatase CDC25A and Bad [252].
 Pim kinases also stimulate mTORC1 activity by 
phosphorylation of 4E-BP1, eIF4E and PRAS [255-258]. 
PDK1 activation also results in resistance to rapalogs 
[259]. This results in PDK1 phosphorylation of c-Myc 
after rapamycin treatment. Altering the levels of 4E-
BP1 (decreasing) or eIF4E (increasing) can result in 
resistance to rapamycin [260]. Some cells deficient in 
p27Kip-1 are resistance to rapamycin as rapamycin normally 
prevents p27Kip-1 down regulation [261]. There are other 
mechanisms of resistance to rapamycin. One group has 
determined that the levels of cyclin E-dependent kinase 
activity are altered in resistant hepatic cells [262] 
Increased oxidative stress induces mTORC1 
modification which prevents its ability to bind the 
FKBP-12/rapamycin complex [263]. High levels of 
reactive oxygen species (ROS) promote resistance to 
rapalogs. mTOR kinase inhibitors may be able to inhibit 
ROS mediated rapalog resistance as they inhibit mTOR 
independently of FKBP-12 [264]. Overexpression of 
Bcl-2 and survivin can make certain cells resistant to the 
apoptosis normally induced by rapalogs [265]. Inhibition 
of angigogenesis is a potent aspect of rapalogs in vivo 
[266]. Since HIF-1-alpha controls VEGF expression, 
tumors with decreased VEGF expression are more 
resistant to rapalogs. There are other strategies to 
overcome mTOR resistance being examined. The effects 
of combined dual targeting of mTOR and HSP90 are being 
investigated [267]. 
mtor Inhibitors
Small molecules designed for inhibiting the 
catalytic site of mTOR have shown promising effects on 
suppression of signaling downstream of mTOR. mTOR 
kinase inhibitor have been developed which directly 
inhibit mTORC1 and mTORC2. The mTOR kinase 
inhibitors have advantages over rapamycin and rapalogs 
as the mTOR inhibitors will inhibit both mTORC1 and 
mTORC2 while rapamycin and rapalogs predominantly 
inhibit mTORC1. Also the mTOR kinases inhibitors do 
not induce the feedback pathways which result in Akt 
activation. 
OSI-027 is a pan mTOR inhibitor developed by 
OSI Pharmaceuticals/Astellas Pharma Inc. OSI-027 is 
effective in inducing apoptosis in different types of cancer, 
including breast and leukemias [268,269]. OSI-027 has 
been shown to inhibit the growth of imatinib-resistant 
CML cells which contain the BCR-ABL T315I mutation 
that are resistant to all BCR-ABL inhibitors [270]. OSI-
027 has been evaluated in a clinical trial (NCT00698243) 
with patients with advanced solid tumors and lymphoma 
[271].
PP-242 is a potent inhibitor of both mTORC1 
and mTORC2 developed by Intellikine. INK-128 is a 
derivative of PP-242 which has shown anti-tumoral effects 
on multiple cancer types including RCC, MM, NHL 
and prostate neoplasia [272-274]. INK-128 is in phase I 
clinical trials (NCT01118689) for patients with relapsed 
or refractory MM or Waldenstrom macroglobulinemia or 
patients with solid malignancies (NCT01058707).
AZD8055 and AZD2014 are pan mTOR inhibitors 
with potent anti-tumor activity that have been developed 
by AstraZenica [275,276]. They are being evaluated in 
a clinical trial (NCT01316809) with individuals with 
gliomas who have not responded to standard glioma 
therapies as well as other types of cancer patients.
Palomid 529 (Paloma Pharmaceuticals) is a pan 
mTOR inhibitor which has potent anti-tumor affects and 
reduces tumor angiogenesis and vascular permeability 
[277]. Palomid 529 is undergoing phase I clinical trials 
for patients with macular degeneration (NCT01033721).  
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WAY600, WYE353, WYE687 and WYE132 were 
developed by Wyeth (Pfizer). These inhibitors were 
derived from WAY001 which was more specific for 
PI3K-alpha than either mTORC1 or mTORC2. These 
inhibitors were optimized which resulted in WYE132 
(WYE125132)/ WYE132 has 5000-fold greater selectivity 
for mTOR over PI3K. It caused tumor regression in breast, 
glioma, lung, renal tumors [278]. 
Many other mTOR inhibitors have been described 
which include: Ku0063794 (KuDOS Pharmaceuticals) 
[279] and OXA-01 (OSI Pharmaceuticals) [280]. 
Torin2 has been developed by optimizing Torin1 [282]. 
TORKiCC223 is a pan mTOR inhibitor developed 
by Celgene. Other companies are developing mTOR 
inhibitors; clearly this is a very competitive but important 
research and clinical area. 
Metformin is an indirect inhibitor of mTORC1. 
Metformin induces AMPK which turns on TSC1 which 
suppresses mTORC1 activity [8,282]. Metformin may 
also induce the phosphorylation and inactivation of 
Raptor [283].  Diabetics treated with metformin have 
lower incidences of cancer and also do not exhibit as much 
aging [284,285]. Metformin may be able to prevent the 
survival of certain CICs. Enhanced glycolysis (Warburg 
effect) is critical for CICs [286-289]. Metformin disrupts 
the glycolytic metabotype and alters the ATM-mediated 
DNA damage response resulting in the acceleration of 
stress-induced sencescence. Metformin in the presence of 
suppressed mTOR signaling slows down aging and alters 
the cellular senescence processes.  Hence metformin can 
alter the ability of cells to become immortalized into CICs 
and slows down aging. By reducing the levels of DNA 
damage signaling, metformin has genoprotective affects 
[290,291]. 
 A phase I clinical trial (NCT00659568) was 
performed on analyzing the effects of combining 
metformin with temsirolimus in patients with metastatic or 
unresectable solid tumor or lymphomas and demonstrated 
disease stabilization [292]. 
Inhibition of RHEB by farnesyltransferase (FT) 
inhibitors is another mechanism to inhibit mTORC1 [293]. 
FT inhibitors have been extensively examined in clinical 
trials [294]. 
PP2A Activators
Successful targeting of the protein phosphatases 
has in general not proceeded as rapidly as targeting of 
protein kinases. FTY720 (fingolimod) is a PP2A activator 
which has been approved as an immunomodulator 
for oral use in patients with multiple sclerosis [295]. 
Reactivation of PP2A activity by FTY720 suppressed 
cell growth, enhanced apoptosis, impaired clonogenicity, 
and decreased in vivo leukemogenesis of imatinib- and 
dasatinib-sensitive and -resistant Ph+ B-ALL cells, as well 
as Ph+ B-ALL progenitors (CD34+/CD19+). Importantly, 
healthy CD34+ and CD34+/CD19+ bone marrow cells 
were unaffected by FTY720. Furthermore, pharmacologic 
doses of FTY720 suppressed in vivo BCR-ABL-driven 
leukemogenesis (including leukemogenesis promoted by 
the BCR-ABL T315I mutant which is resistant to imatinib 
and second generation TKIs) without exerting any toxicity 
in mice [296].
Increasing the Effectiveness of targeting the 
raf/MEK/ErK and PI3K/PtEn/Akt/mtor 
Pathways by simultaneous treatment with two 
Pathway Inhibitors. 
The obvious goal of current inhibitor development 
is to improve the effectiveness of treatment of cancer 
patients with small molecule signal transduction inhibitors. 
This has proven to be difficult for multiple reasons: first, 
as previously discussed, there tends to be a distinct genetic 
susceptibility for the success of a signal transduction 
inhibitor in suppressing growth, second, many of the small 
molecule signal transduction inhibitors are cytostatic as 
opposed to being cytotoxic and therefore will need to 
be combined with a therapeutic modality that induces 
cell death, and third, more than one signal transduction 
pathway may be activated in the cancer cells, which will 
be discussed in detail below.
Previously, we have predominantly discussed 
studies that employed a single Raf or MEK inhibitor, 
sometimes in combination with a chemotherapeutic 
drug. In the following section, we discuss the potential 
of combining inhibitors that target two pathways to more 
effectively limit cancer growth. In addition to the BRAF 
mutations present in melanomas that we have previously 
discussed, the PTEN phosphatase tumor suppressor gene is 
also deleted in approximately 45% of melanomas and the 
downstream AKT gene is amplified in approximately 45%. 
Both of these mutations result in increased expression/
activity of Akt which is often associated with a poor 
prognosis in human cancer. Increased Akt expression 
will lead to mTOR activation and increased efficiency of 
protein translation. Preclinical studies performed in human 
melanoma cell lines have highlighted that co-targeting of 
the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways 
with Raf and Akt/mTOR inhibitors resulted in synergistic 
inhibition [297]. Treatment of inducible murine lung 
cancers containing KRAS and PIK3CA mutations with 
PI3K/mTOR (NVP-BEZ235) and MEK (selumetinib) 
inhibitors led to an enhanced response [298]. Synergistic 
responses between sorafenib and mTOR inhibitors were 
observed in xenograft studies with a highly metastatic 
human HCC tumor [299]. Some recent studies in thyroid 
cancer have documented the benefit of combining Raf and 
PI3K/mTOR inhibitors [300]. 
Intermittent dosing of MEK and PI3K inhibitors has 
been observed to suppress the growth of tumor xenografts 
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in mice [87]. This study demonstrated that continuous 
administration of MEK and PI3K inhibitors is not required 
to suppress xenograft growth. These important results 
were obtained by performing washout studies in vitro and 
alternate dosing schedules in mice with MEK and PI3K 
inhibitors with BRAF and KRAS mutant cancer cells.
The combined effects of inhibiting MEK with PD-
0329501 and mTOR with rapamycin or its analog AP-
23573 (ARIAD Pharmaceuticals/Merck) were examined 
in human NSCLC cell lines, as well as in animal models 
of human lung cancer [301]. PD-0325901 and rapamycin 
demonstrated synergistic inhibition of proliferation and 
protein translation. Suppression of both MEK and mTOR 
inhibited ribosomal biogenesis and was associated with a 
block in the initiation phase of translation. The pan mTOR 
inhibitor AZD-8055 has been examined as a single agent 
and in combination with the MEK inhibitor AZD-6244 in 
a NSCLC xenograft model. The combination resulted in 
increased cell death and tumor regression [275,302]. These 
preclinical results support suppression of both the MEK 
and mTOR pathways in lung cancer therapy and indicate 
that both pathways converge to regulate the initiation 
of protein translation. ERK phosphorylates Mnk1/2 
and p90Rsk, which regulate the activity of the eukaryotic 
translation initiation factor eIF4E. The phosphorylation 
of 4EBP1 is altered in cells with the BRAF mutation. It 
should also be pointed out that the 4EBP1 is also regulated 
by Akt, mTOR and p70S6K. This may result in the 
efficient translation of certain mRNAs in BRAF-mutant 
cells. This could explain how co-inhibition of MEK and 
mTOR synergize to inhibit protein translation and growth 
in certain lung cancer cells. mTOR inhibitors have been 
combined with HSP90 inhibitors to overcome resistance 
to rapamycin [267].
The effects of combining the MEK inhibitor 
RDEA119 and rapamycin have been examined in various 
cancers including pancreatic cancer [303]. The effects of 
dual inhibition of IGF-1R and mTOR have been examined 
in myeloma and other cancers [304]. Also the effectiveness 
of combination of rapalogs and EGFR inhibitors to 
inhibit glioblastoma growth is being examined [305]. The 
antiproliferative effects of the Akt inhibitor perifosine 
is improved when combined with nanoparticle-bound 
rapamycin on multiple myeloma cells [306]. 
Treatment of vemurafenib-resistant BRAF-mutant 
colorectal cancer cells with an Akt inhibitor (MK-2206) 
overcame their resistance to vemurafenib [307]. Heat 
shock inhibitors such as the HSP90 inhibitor XL888, have 
been shown to inhibit proliferation of some vemurafenib-
resistant melanoma cells [308]. XL888 increased pro-
apoptotic Bim expression and decreased Mcl-1 expression. 
Also decreases in PDGFR-beta, COT, IGF-1R, Raf-1, 
A-Raf, S6, cyclin D1 and Akt were observed. This lead 
to nuclear accumulation of FOXO3a and resulted in 
expression of the proapoptotic Bim protein.
clinical trials based upon Inhibiting both the 
raf/MEK/ErK and PI3K/PtEn/Akt/mtor 
Pathways. 
Combinations of Raf and PI3K/mTOR or MEK and 
PI3K/mTOR inhibitors are in clinical trials. The results 
of a phase 1 clinical trial on patients with advanced solid 
tumors indicate that the combined dosing appears to be 
well tolerated, at least as well as single agent dosing. Some 
anti-tumor effects were observed and dose-escalation trials 
were performed [309]. NCT01138085 is a clinical trial 
combining MEK and Akt inhibitors (GSK1120212 and 
GSK2141795 respectively).  NCT01347866 is a clinical 
trial for patients with advanced cancers combining the 
PI3K/mTOR inhibitors (PF-04691502 & PF-05212384) 
with the MEK inhibitor (PD-0325901) or irinotecan. The 
study will include patients with metastatic CRC who have 
received previous therapy for their disease and whose 
cancers have a mutant KRAS gene. The dual PI3K/mTOR 
inhibitor NVP-BEZ235 is in a combination clinical trial 
(NCT01482156) with RAD001 (everolimus) in patients 
with advanced solid cancers. A phase 1 clinical trial 
(NCT01337765) is in progress combining the MEK1/2 
inhibitor MEK162 and the PI3K/mTOR dual inhibitor 
NVP-BEZ-235. This combination will be evaluated in 
various cancer patients, for example in NSCLC patients 
containing mutations at EGFR who have progressed after 
treatment with EGFR inhibitors or with patients with triple 
negative breast, CRC, melanoma, and pancreatic cancers. 
In addition, patients with other advanced solid tumors with 
KRAS, NRAS, and/or BRAF mutations will be included 
in this trial.  NCT01390818 is a research trial testing a 
combination of two experimental drugs, MSC1936369B 
(a MEK inhibitor) and SAR245409 (a PI3K/mTOR 
inhibitor), (EMD Serono and Sanofi) for the treatment 
of locally advanced or metastatic solid tumors. Patients 
with breast, NSCLC, melanoma and colorectal cancers 
will be treated with this inhibitor combination. A clinical 
trial NCT01021748 is examining the effects of combining 
MK2206 (Akt inhibitor) and AZD6244 (selumetinib, 
MEK inhibitor) in cancer patients with advanced solid 
tumors. NCT01519427 is a clinical trial combining 
the MEK inhibitor selumetinib and the Akt inhibitor 
MK2206 in patients with stage III or stage IV melanoma 
that previously failed after treatment with vemurafenib 
or dabrafenib. A diagram illustrating potential combined 
inhibitor therapy to overcome resistance is presented in 
Figure 5.
Enhancing Effectiveness of raf/MEK and PI3K/
Akt/mtor Inhibitors with chemotherapy.
 Classical chemotherapy often remains the most 
prescribed anti-cancer therapy for many different types 
of cancer treatment. Optimizing chemotherapy with 
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targeted therapy may require genetic analysis to obtain 
the best response which may also depend on the timing 
of individual drug treatment [310-320].  Drugs such as 
doxorubicin and taxol are effective in the treatment of 
many cancers, even though in some cases drug resistance 
develops after prolonged treatment. Doxorubicin, taxol and 
other chemotherapeutic drugs alter cellular events, such as 
DNA replication [321], DNA repair [322], cell division 
[323-325], polyploidy [326], autophagy [327,328], 
angiogenesis [329] or the tumor microenvironment 
[330]. Often the effects of the chemotherapeutic drug are 
dependent upon the TP53 gene status [331-334]. 
Chemotherapeutic drugs can activate the Ras/
Raf/MEK/ERK pathway by diverse mechanisms. Drugs 
such as doxorubicin can activate p53 which can lead to 
increased expression of the discoidin domain receptor 
(DDR), which in turn can result in Raf/MEK/ERK 
pathway activation. Activated ERK can phosphorylate p53 
and regulate its activity. Doxorubicin can also activate the 
calcium calmodulin dependent kinase (CaM-K) cascade 
via ROS [4,335]. Activation of this cascade can also 
result in stimulation of the Raf/MEK/ERK cascade which 
induces the transcription of genes which are involved in 
DNA repair and lead to drug resistance [4,335]. Taxols can 
also stimulate activation of the Raf/MEK/ERK cascade 
and lead to their increased association with proteins 
involved in cell division [336,337] Thus, by combining 
classical chemotherapy with targeted therapy, it may be 
possible to enhance toxicity, while lowering the prescribed 
concentrations of classical chemotherapeutics necessary 
for effective elimination of the tumor [337]. Activation 
of the Raf/MEK/ERK cascade can alter the activity and 
subcellular localization of many proteins that play critical 
roles in apoptotic cascades. Also the Raf/MEK/ERK 
cascade can regulate the transcription of many critical 
genes involved in cell cycle progression, growth and 
differentiation [3,4].
The 5 year survival rate for CRC is less than 10%, 
thus novel therapies are required to improve treatment 
of this cancer. KRAS is often mutated in CRC, thus the 
Raf/MEK/ERK pathway will be activated. The effects of 
combining the MEK inhibitor selumetinib with vorinostat 
[a histone deacetylase (HDAC) inhibitor] were examined 
in a recent study [338]. Combining the two inhibitors 
resulted in a synergistic response in vitro, while an 
additive response was observed in vivo. 
Treatment of mice xenografted with vemurafenib-
resistant BRAF-mutant CRCs with various combinations 
of vermurafenib and chemotherapeutic drugs 
(capecitabine, irinotecan), monoclonal antibodies 
[bevacizumab a.k.a avastin, targets VEGF-alpha, Roche/
Genentech), cetuximab (a.k.a erbitux, targets EGFR, 
Imclone/Eli Lilly)], or the small molecule Akt inhibitor 
MK-2206, or the EGFR inhibitor erlotinib increased 
survival [307]. Combination of the Akt inhibitor MK-
2206 and either EGFR/HER2 targeted therapy [erlotinib 
(a.k.a tarceva, an EGFR inhibitor from Genenetec/OSI/
Roche) or lapatinib (a.k.a. tykerb, a dual EGFR and 
HER2 inhibitor from GSK) or chemotherpapeutic drugs 
(doxorubicin, camptothechin, gemcitabine, 5-flurouracil, 
docetaxel or carboplatin resulted in synergistic responses 
in lung (NCI-H460) and ovarian (A2780) cancer cell lines. 
In some cases, the timing of drug addition was determined 
to be important as MK-2206 suppressed the Akt activation 
induced by carboplatin and gemcitabine [339]. The effects 
of combining the dual PI3K/mTOR inhibitor NVP-
BEZ235 and various chemotherapeutic drugs as well as 
other targeted therapies are being examined (doxorubicin, 
melphalan, vincristine, bortezomib) [340,341]. The effects 
of the pan mTOR inhibitor INK-128 could be enhanced by 
the addition of sorafenib and avastin [272,273]. A clinical 
trial (NCT01351350) with INK-128 in combination with 
paclitaxel, either in the absence or presence of herceptin, is 
in progress in patients with advanced solid malignancies. 
The anti-tumor effects of the mTOR inhibitor WYE132 
could be enhanced upon combination with avastin in lung 
and breast xenograft models [278]. 
Clinical trials are ongoing based on combining 
NVP-BEZ235 using inhibitors (BKM120, MEK162) and 
the chemotherapeutic drug (paclitaxel) and herceptin to 
treat advanced solid cancers and metastatic breast cancers 
which are difficult to treat (see below).  BKM120 is a pan-
PI3K inhibitor. It is being included in some clinical studies 
since NVP-BEZ235 does not inhibit PI3K-P110-β [242]. 
Furthermore NVP-BEZ235 is not effective in suppressing 
the growth of tumors which have the KRAS G12D 
mutation [343].   Thus to achieve effective suppression of 
cancer growth in some situations, it maybe be important to 
combine PI3K/mTOR inhibitors with pan PI3K inhibitors. 
Palomid 529, a pan mTOR inhibitor, in some 
circumstances is effective as a single agent. Importantly 
when Palomid 529 was combined with either cisplatin 
or docetaxel it had a better effect on hormone-refractory 
prostate cancers [344]. It also improved the effects of 
radiotherapy on prostate cancer cells [345].  
As mentioned previously, a side effect of some 
chemotherapeutic drugs, such as paclitaxel, is the 
induction of the Raf/MEK/ERK pathway. Activation of 
this pathway, can under certain circumstances, promote 
proliferation and prevent apoptosis. Also the PI3K/PTEN/
Akt/mTOR pathway can modulate the Raf/MEK/ERK 
pathway and altering MEK activity can have opposing 
effects on different cell types [346-349]. Combining 
paclitaxel treatment with PI3K inhibitors enhances 
apoptosis and inhibits growth of ovarian carcinoma 
cell lines, and this may have been mediated in part by 
suppression of inhibitory phosphorylation of Raf by Akt 
[346]. In addition, the effects of combined treatment 
with MEK inhibitors and paclitaxel have been examined. 
The synergistic effects of paclitaxel and MEK inhibitors 
are complex and not fully elucidated, but may be in part 
mediated by inhibition of Bad phosphorylation at S112 by 
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ERK in UM-SCC-23 squamous carcinoma cell line [348]. 
The cytotoxic effects of combinations of MEK 
inhibitors and paclitaxel may be specific for cells 
of certain origins and may depend on the levels of 
endogenous activated MEK/ERK present in those cells. In 
a study with NSCLC cells which constitutively-expressed 
activated MEK/ERK, no increase in paclitaxel-induced 
apoptosis was observed when the cells were treated with a 
MEK inhibitor [347]. In contrast, addition of a dominant 
negative (DN) MEK gene to these cells potentiated 
paclitaxel-induced apoptosis.
Cisplatin-induced apoptosis was associated with 
increased levels of both p53 and the downstream Bax 
protein in a study with neuroblastoma cells [348]. 
Activated ERK1/ERK2 levels also increased in these 
cells upon cisplatin treatment.  MEK inhibitors blocked 
apoptotic cell death, which prevented the cisplatin-induced 
accumulation of p53 and Bax proteins [348].
It should be noted that the combination of MEK 
inhibitors and chemotherapeutic drugs may not always 
result in a synergistic interaction leading to cell death. In 
some cases, combination therapy results in an antagonistic 
response. For example, combining MEK inhibitors 
with betulinic acid, a drug toxic for melanoma cells, 
antagonized the normal enhancing effects of betulinic 
acid on apoptosis in vitro [349]. Furthermore, the precise 
timing of the addition of two agents is important as they 
may differentially affect cell-cycle progression; therefore, 
the order of administration may be important for a 
synergistic response to be obtained and perhaps to prevent 
an antagonistic response. 
There are few effect therapeutic options for HCC. 
Combination of rapamycin with conventional cytostatic 
drugs such as doxorubicin and vinblastine enhances the 
antineoplastic activity of the respective monotherapeutic 
HCC treatment obtained with either doxorubicin or 
vinblastine alone [350,351]. Taken together, the in vitro 
and preclinical in vivo data as well as the clinical trials 
conducted so far demonstrate that mTOR inhibitors are 
promising agents for HCC treatment, particularly in 
combination with conventional chemotherapeutic drug 
therapy. 
The effects of sorafenib on the treatment of HCC 
patients were examined in a clinical trial [350]. A phase 
II trial demonstrated that the combination of sorafenib 
and doxorubicin improved progression-free and overall 
survival of patients with advanced HCC [351]. Moreover, 
a phase II trial (NCT00464919) was performed to 
determine the progression-free survival of sorafenib plus 
tegafur/uracil (UFUR) for the treatment of advanced or 
metastatic HCC. The study indicated that UFUR can be 
safely combined with sorafenib and may improve the 
efficacy of sorafenib in advanced HCC patients [352]. 
The effects of inhibiting Akt in combination with 
other signaling pathways and chemotherapy are being 
evaluated in numerous phase I clinical trials. These trials 
highlight the importance of targeting multiple molecules to 
suppress the growth of cancer which are resistant to most 
therapies.  A combination clinical trial (NCT01245205) 
with the Akt inhibitor MK-2206 and the dual EGFR/
HER2 inhibitor lapatinib is in progress with patients 
having advanced or metastatic solid tumors or breast 
cancer patients. NCT00848718 is a clinical trial with 
patients having advanced cancers to examine the effects 
of combining MK-2206 and the EGFR inhibitor erlotinib, 
docetaxel, or carboplatin + paclitaxel. NCT00963547 
was a clinical trial with HER2+ breast cancer patients 
to examine the effects of combining MK2206 with 
trastuzumab (herceptin) and lapatinib. NCT01245205 and 
NCT01281163 are clinical trials examining the effects 
of combining MK2206 with lapatinib in cancer patients 
with advanced or metastatic solid tumors or breast cancer 
or just breast cancers, respectively.  NCT01147211 is a 
clinical trial with NSCLC patients examining the effects 
of combining MK-2206 with gefitinib (a.k.a. Iressa, EGFR 
inhibitor developed by AstraZenica). NCT01344031 is 
a clinical trial with post menopausal metastatic breast 
cancer patients examining the effects of combining 
anastrozole, letrozole, exemestane (aromatase-inhibitors), 
or fulvestrant (an estrogen receptor antagonist). 
NCT01369849 is a clinical trial examining the effects 
of combining MK2206, with bendamustin (nitrogen 
mustard alkylating agent) and rituximab (a.k.a. Rituxan, a 
chimeric monoclonal antibody targeting CD20 from IDEC 
Pharmaceuticals/Genenetec) on CLL cancer patients who 
have relapsed or cancer patients with small lymphocytic 
lymphoma. NCT01243762 is a clinical trial combining 
MK-2206 and dalotuzumab (monoclonal Ab targeting 
IGF-1R from Merck), MK-0752 a (Y-secretase inhibitor 
which inhibits the NOTCH pathway from Merck) and 
dalotuzumab and MK-8669 (ridaforolimus a mTOR 
inhibitor from Merck) and dalotuzumab in cancer patients 
with advanced cancers. NCT01263145 is a clinical trial 
combining MK2206 and paclitaxel in cancer patients 
with locally advanced or metastatic solid tumors or 
metastatic breast cancers. The above mentioned clinical 
trials document the importance of targeting Akt and other 
signaling molecules as well as critical targets involved in 
cellular division. Furthermore the clinical trials document 
how basis research experimentation on these pathways is 
being translated into clinical therapy for cancer and other 
types of patients.
Enhancing Effectiveness of raf/MEK and PI3K/
mtor Inhibitors with radiotherapy.
 Radiotherapy is a common therapeutic approach for 
treatment of many diverse cancers [353]. Radiotherapy 
often induces DNA double strand breaks [354]. The 
successfulness of radiotherapy is often governed by the 
functionality of p53 and its affects on apoptosis [355,356]. 
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The ability to improve the effects of radiotherapy with 
small molecule inhibitors is an area of active research 
interest [357]. 
A side effect of radiotherapy in some cells is 
induction of the Ras/Raf/MEK/ERK cascade [3,4]. 
Various signal transduction inhibitors have been evaluated 
as radiosensitizers. The effects of pre-treatment of lung, 
pancreatic and prostate cancer cells with selumetinib 
were evaluated in vitro using human cell lines and in vivo 
employing xenografts [358]. The MEK inhibitor treatment 
radiosensitized various cancer cell lines in vitro and in 
vivo. The MEK inhibitor treatment was correlated with 
decreased Chk1 phosphorylation 1-2 hrs after radiation. 
The authors noticed the effects of the MEK inhibitor 
on the G2 checkpoint activation after irradiation, as the 
MEK inhibitor suppressed G2 checkpoint activation. Since 
ERK1/ERK2 activity is necessary for carcinoma cells to 
arrest at the G2 checkpoint, suppression of phosphorylated 
Chk1 was speculated to lead to the abrogated G2 
checkpoint, increased mitotic catastrophe and impaired 
activation of cell cycle checkpoints. Chk1/Chk2 as serine/
threonine kinases. Chk/Chk2 are important controlling 
regulators of DNA repair and cell cycle progression. DNA 
damage responses which signal through ATM and ATR 
activate the DNA damage transducers Chk1 and Chk2 
[359-383].
Mitotic catastrophe was increased in cancer cells 
receiving both the MEK inhibitor selumetinib and 
radiation when compared to the solo-treated cells [358]. 
Suppression of MEK activity resulted in decreased 
phosphorylated Chk1 leading to the abrogated G2 
checkpoint. It was also postulated in this study that 
the MEK inhibitor suppressed the autocrine cascade 
in DU145 prostate cancer cells that normally resulted 
from EGF secretion and EGFR activation. Suppression 
of this autocrine cascade by the MEK inhibitor may 
have served as a radiosensitizer to the radiation therapy. 
The other two cancer cell lines examined in this study 
(A549 and MiaPaCa2) had KRAS mutations and both 
were radiosensitized by the MEK inhibitor. Although 
these studies document the ability of a MEK inhibitor 
to radiosensitize certain cells, clearly other cancer cell 
lines without activating mutations in the Ras/Raf/MEK/
ERK pathway or autocrine growth stimulation should be 
examined for radiosensitization by the MEK inhibitor as 
the KRAS mutation may also activate the PI3K pathway 
which could lead to therapy resistance.
PI3K/Akt/mTOR inhibitors will sensitize the tumor 
vasculature to radiation both in vitro in cell lines and in 
vivo in xenografts [384,385]. mTOR and radiation play 
critical roles in the regulation of autophagy [386,387]. 
These studies document the potential beneficial use of 
combining mTOR inhibitors and radiation to improve the 
induction of autophagy in the treatment of solid tumors. 
This is important as apoptotic cell death is a minor 
component to cell death in solid tumors.  When mTOR is 
blocked by rapamycin there is an increase in autophagy 
[388-393]. mTORC1 is a repressor of autophagy, a 
lysosome-dependent degradation pathway which allows 
cells to recycle damaged or superfluous cytoplasmic 
content, such as lipids, proteins, and organelles. As 
a consequence, cells produce metabolic precursors 
for macromolecular biosynthesis or ATP generation 
[392]. In cancer cells, autophagy fulfils a dual role, as 
it has both tumor-promoting and tumor-suppressing 
properties. Autophagy is also an important component 
in hematopoietic cancers and some therapy-resistant 
cells have defects in autophagy [394-396] Functional 
autophagy prevents necrosis and inflammation, which 
can lead to genetic instability. However, autophagy might 
be important for tumor progression by providing energy 
through its recycling mechanism during unfavorable 
metabolic circumstances, which are very common in 
tumors [397-399].  
conclusIons
Inhibitors to the Ras/Raf/MEK/ERK and Ras/
PI3K/PTEN/Akt/mTOR pathways have been isolated and 
developed by various screening approaches and then in 
some cases modified by medicinal chemistry. Initially 
MEK and mTOR inhibitors were demonstrated to have 
the most specificity. However, MEK inhibitors may have 
limited effectiveness in treating human cancers, unless 
the particular cancer proliferates directly in response 
to the Raf/MEK/ERK pathway. A similar scenario is 
also true with mTOR inhibitors, they are most effective 
when there is a mutation which deregulates the PI3K/
PTEN/Akt/mTOR pathways. Moreover, MEK inhibitors 
are often cytostatic as opposed to cytotoxic, thus their 
ability to function as effective anti-cancer agents in a 
monotherapeutic setting is limited, and they may be more 
effective when combined with chemo- or radiotherapy 
or an inhibitor which targets a different pathway or even 
an inhibitor which targets the same pathway. Rapamycin 
and rapalogs are being used to treat certain cancers which 
proliferate in response to mutations in regulatory genes 
which control the PI3K/PTEN/Akt/mTOR pathway. Raf 
inhibitors have also been developed and some are being 
used to treat various cancer patients (e.g., sorafenib, HCC). 
This particular Raf inhibitor also inhibits other receptors 
and kinases which may be required for the growth of the 
particular cancer. This promiscuous nature of sorafenib 
has contributed to the effectiveness of this particular 
Raf inhibitor for certain cancers. Raf inhibitors such as 
vemurafenib, dabrafenib, and GDC-0879 are promising 
for the treatment of melanoma, CRC, thyroid and other 
solid cancers and leukemias/lymphomas/myelomas which 
have mutations at BRAF V600E. However, problems have 
been identified with certain BRAF mutant allele inhibitors 
as they will also result in Raf-1 activation if RAS is 
mutated/amplified of if an exon of BRAF is deleted, or 
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if BRAF is amplified or if there are mutations at MEK1 
and other genetic mechanisms. Combination therapy with 
either a traditional drug/physical treatment or another 
inhibitor that targets a specific molecule in a different 
signal transduction pathway is also a key approach for 
improving the effectiveness and usefulness of MEK and 
Raf inhibitors. 
Modified rapamycins, rapalogs are being used to 
treat various cancer patients, (e.g., patients with RCC). 
While rapalogs are effective and their toxicity profiles 
are well known, one inherent property is that they are 
not very cytotoxic when it comes to killing tumor cells. 
This inherent property of rapamycins, may also contribute 
to their low toxicity in humans. Interestingly and highly 
relevant, it has been observed that certain inhibitors which 
target “growth and metabolism” such as rapamycin and 
metformin may have very potent anti-cancer and anti-
aging effects [233-239, 284-291]
Mutations at many of the upstream receptor genes 
or RAS can result in abnormal Raf/MEK/ERK and PI3K/
PTEN/Akt/mTOR pathway activation. Hence targeting 
these cascade components with small-molecule inhibitors 
may inhibit cell growth. The usefulness of these inhibitors 
may depend on the mechanism of transformation of the 
particular cancer. If the tumor exhibits a dependency on 
the Ras/Raf/MEK/ERK pathway, then it may be sensitive 
to Raf and MEK inhibitors. In contrast, tumors that do 
not display enhanced expression of the Ras/Raf/MEK/
ERK pathway may not be sensitive to either Raf or MEK 
inhibitors but if the Ras/PI3K/Akt/mTOR pathway is 
activated, it may be sensitive to specific inhibitors that 
target this pathway. Some promising recent observations 
indicate that certain CICs may be sensitive to mTOR 
inhibitors [3,4.6,7,195,196,216,400-404] and metformin 
[8,129,269,286,287,405,406], documenting their potential 
use in the elimination of the cells responsible for cancer 
re-emergence. Finally, it is likely that many of the 
inhibitors that we have discussed in this review will be 
more effective in inhibiting tumor growth in combination 
with cytotoxic chemotherapeutic drugs or radiation. 
Some scientists and clinicians have considered that 
the simultaneous targeting of Raf and MEK by individual 
inhibitors may be more effective in cancer therapy than 
just targeting Raf or MEK by themselves. This is based 
in part on the fact that there are intricate feed-back loops 
from ERK which can inhibit Raf and MEK. For example 
when MEK1 is targeted, ERK1,2 is inhibited and the 
negative feed-back loop on MEK is broken and activated 
MEK accumulates. However, if Raf is also inhibited, it 
may be possible to completely shut down the pathway. 
This is a rationale for treatment with either dual Raf/MEK 
inhibitors or simultaneously with both Raf and MEK 
individual inhibitors. Likewise targeting both PI3K and 
mTOR may be more effective than targeting either PI3K 
or mTOR by themselves. If it is a single inhibitor which 
targets both molecules, such as the new PI3K and mTOR 
dual inhibitors this becomes a realistic therapeutic option. 
Also in some cases it may be necessary to eliminate the 
cancer by treatment with a dual PI3K/mTOR inhibitor as 
well as with an additional PI3K inhibitor which suppresses 
the PI3K-p110-delta isoform as certain dual PI3K/mTOR 
inhibitors do not effectively suppress this isoform. Finally, 
an emerging concept is the dual targeting of two different 
signal transduction pathways, Raf/MEK/ERK and PI3K/
PTEN/Akt/mTOR for example. This has been explored 
in some preclinical models as well as clinical trials as 
discussed in the text. The rationale for the targeting of 
both pathways may be dependent on the presence of 
mutations in either/or both pathways or in upstream Ras 
in the particular cancer which can activate both pathways. 
It is not always clear why a particular combination 
of a signal transduction inhibitor and chemotherapeutic 
drug works in one tumor type but not at all in a different 
tumor type. This has also been experience with the 
development of individual chemotherapeutic drugs, some 
work in some cancers but not others. This may result 
from many different complex interacting events. Some of 
these events could include: percentage of cells in different 
phases of the cell cycle, persistence of CICs, presence of 
multiple mutated activated oncogene or repressed tumor 
suppressor genes, epigenetic modifications and many 
other factors. Finally, chemotherapeutic drug therapy and 
other types of therapy (radiotherapy, antibody therapy) 
may induce certain signaling pathways (e.g., the ROS 
generated by chemotherapy and radiotherapy induce the 
Ras/Raf/MEK/ERK pathway). The induction of these 
signalling pathways may counteract some of the effects of 
the signal transduction inhibitors.
A problem with some of the preceding studies is 
that most of the resistant cells were derived after culturing 
cells in vitro for prolonged periods of time in the presence 
of increasing doses of B-Raf inhibitors. The clinical 
relevance of these mechanisms of resistance awaits 
their identification in resistant samples from melanoma 
and other cancer patients treated with these inhibitors. 
Furthermore, many of the studies were performed on 
different established melanoma cell lines which have 
various additional mutations besides those in BRAF that 
may or may not be relevant for actual melanomas present 
in patients. Finally the various melanoma cell lines may 
be at different stages of differentiation and thus the genes 
involved in resistance in vitro, may be different from what 
is observed in other classes (stages of differentiation) of 
melanoma in vivo. Interesting, increased drug transporter 
activity has not been reported in the limited number of 
B-Raf inhibitor-resistant samples investigated, where 
it has been observed in other cancer types treated with 
diverse small molecule inhibitors and/or chemotherapeutic 
drugs.
Scientists and clinicians often have an intentionally 
narrow view of a particular topic. For example, cancer 
researchers predominantly feel that Raf, MEK, PI3K, 
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Akt and mTOR inhibitors will suppress the growth 
of malignant cancer cells. Yet MEK and mTOR and 
other inhibitors may also be useful in the treatment of 
autoimmune or allergic disorders where there is abnormal 
cellular proliferation. Recently it has been observed that 
the suppression of the Ras/Raf/MEK/ERK and Ras/PI3K/
Akt/mTOR pathways may prevent the induction of cellular 
senescence and aging. Clearly, these later two clinical 
topics, immune disorders and aging, greatly enhance the 
potential clinical uses of these targeted therapeutic drugs. 
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